WO2011005761A8 - Novel nucleic acid prodrugs and methods of use thereof - Google Patents

Novel nucleic acid prodrugs and methods of use thereof Download PDF

Info

Publication number
WO2011005761A8
WO2011005761A8 PCT/US2010/041068 US2010041068W WO2011005761A8 WO 2011005761 A8 WO2011005761 A8 WO 2011005761A8 US 2010041068 W US2010041068 W US 2010041068W WO 2011005761 A8 WO2011005761 A8 WO 2011005761A8
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
acid prodrugs
methods
novel nucleic
prodrugs
Prior art date
Application number
PCT/US2010/041068
Other languages
French (fr)
Other versions
WO2011005761A1 (en
Inventor
Gregory L. Verdine
Meena Meena
Naoki Iwamoto
Original Assignee
Ontorii, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43429503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2011005761(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to KR1020127003240A priority Critical patent/KR101885383B1/en
Priority to IN720DEN2012 priority patent/IN2012DN00720A/en
Priority to EP10797719.1A priority patent/EP2451461A4/en
Priority to JP2012519668A priority patent/JP5998326B2/en
Priority to RU2012102480A priority patent/RU2612521C2/en
Priority to CN201080039607.0A priority patent/CN102596204B/en
Priority to MX2012000380A priority patent/MX342945B/en
Application filed by Ontorii, Inc filed Critical Ontorii, Inc
Priority to BR112012000828A priority patent/BR112012000828A8/en
Priority to CA2767253A priority patent/CA2767253A1/en
Priority to AU2010270714A priority patent/AU2010270714B2/en
Priority to SG2012001301A priority patent/SG177564A1/en
Priority to US13/381,323 priority patent/US9744183B2/en
Publication of WO2011005761A1 publication Critical patent/WO2011005761A1/en
Priority to IL217370A priority patent/IL217370A/en
Publication of WO2011005761A8 publication Critical patent/WO2011005761A8/en
Priority to AU2015255202A priority patent/AU2015255202B2/en
Priority to US15/167,669 priority patent/US10307434B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Abstract

Described herein are nucleic acid prodrugs and nucleic acid prodrugs comprising chiral phosphorous moieties. Also described herein are methods of making and using nucleic acid prodrugs and nucleic acid prodrugs comprising chiral phosphorous moieties.
PCT/US2010/041068 2009-07-06 2010-07-06 Novel nucleic acid prodrugs and methods use thereof WO2011005761A1 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
BR112012000828A BR112012000828A8 (en) 2009-07-06 2010-07-06 NEW NUCLEIC ACID PRO-DRUGS AND METHODS OF THEIR USE
CA2767253A CA2767253A1 (en) 2009-07-06 2010-07-06 Novel nucleic acid prodrugs and methods of use thereof
IN720DEN2012 IN2012DN00720A (en) 2009-07-06 2010-07-06
AU2010270714A AU2010270714B2 (en) 2009-07-06 2010-07-06 Novel nucleic acid prodrugs and methods use thereof
RU2012102480A RU2612521C2 (en) 2009-07-06 2010-07-06 Novel prodrugs of nucleic acids and their application methods
CN201080039607.0A CN102596204B (en) 2009-07-06 2010-07-06 New nucleic acid prodrugs and using method thereof
MX2012000380A MX342945B (en) 2009-07-06 2010-07-06 Novel nucleic acid prodrugs and methods use thereof.
KR1020127003240A KR101885383B1 (en) 2009-07-06 2010-07-06 Novel nucleic acid prodrugs and methods of use thereof
US13/381,323 US9744183B2 (en) 2009-07-06 2010-07-06 Nucleic acid prodrugs and methods of use thereof
EP10797719.1A EP2451461A4 (en) 2009-07-06 2010-07-06 Novel nucleic acid prodrugs and methods of use thereof
JP2012519668A JP5998326B2 (en) 2009-07-06 2010-07-06 Novel nucleic acid prodrugs and methods of use thereof
SG2012001301A SG177564A1 (en) 2009-07-06 2010-07-06 Novel nucleic acid prodrugs and methods of use thereof
IL217370A IL217370A (en) 2009-07-06 2012-01-04 Nucleic acid prodrugs and methods of use thereof
AU2015255202A AU2015255202B2 (en) 2009-07-06 2015-11-10 Novel nucleic acid prodrugs and methods of use thereof
US15/167,669 US10307434B2 (en) 2009-07-06 2016-05-27 Nucleic acid prodrugs and methods of use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22336909P 2009-07-06 2009-07-06
US61/223,369 2009-07-06
US24272209P 2009-09-15 2009-09-15
US61/242,722 2009-09-15

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/381,323 A-371-Of-International US9744183B2 (en) 2009-07-06 2010-07-06 Nucleic acid prodrugs and methods of use thereof
US15/167,669 Continuation US10307434B2 (en) 2009-07-06 2016-05-27 Nucleic acid prodrugs and methods of use thereof

Publications (2)

Publication Number Publication Date
WO2011005761A1 WO2011005761A1 (en) 2011-01-13
WO2011005761A8 true WO2011005761A8 (en) 2012-02-02

Family

ID=43429503

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/041068 WO2011005761A1 (en) 2009-07-06 2010-07-06 Novel nucleic acid prodrugs and methods use thereof

Country Status (15)

Country Link
US (2) US9744183B2 (en)
EP (1) EP2451461A4 (en)
JP (2) JP5998326B2 (en)
KR (1) KR101885383B1 (en)
CN (1) CN102596204B (en)
AU (1) AU2010270714B2 (en)
BR (1) BR112012000828A8 (en)
CA (1) CA2767253A1 (en)
CL (1) CL2012000021A1 (en)
IL (1) IL217370A (en)
IN (1) IN2012DN00720A (en)
MX (1) MX342945B (en)
RU (1) RU2612521C2 (en)
SG (2) SG177564A1 (en)
WO (1) WO2011005761A1 (en)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009146123A2 (en) * 2008-04-03 2009-12-03 Spring Bank Compositions and methods for treating viral infections
ES2616051T3 (en) 2008-12-02 2017-06-09 Wave Life Sciences Japan, Inc. Method for the synthesis of modified nucleic acids in the phosphorus atom
AU2010270714B2 (en) 2009-07-06 2015-08-13 Wave Life Sciences Ltd. Novel nucleic acid prodrugs and methods use thereof
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
EP2734208B1 (en) * 2011-07-19 2017-03-01 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
JP6246121B2 (en) 2012-07-13 2017-12-13 株式会社新日本科学 Chiral nucleic acid adjuvant
CN107011400B (en) 2012-07-13 2021-05-25 波涛生命科学有限公司 Asymmetric auxiliary group
MX2015000577A (en) * 2012-07-13 2015-08-14 Wave Life Sciences Pte Ltd Chiral control.
US9950001B2 (en) 2012-08-20 2018-04-24 The Regents Of The University Of California Polynucleotides having bioreversible groups
PL2961388T3 (en) * 2013-03-01 2019-10-31 Astex Pharmaceuticals Inc Drug combinations
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
US10149905B2 (en) 2014-01-15 2018-12-11 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
KR102423317B1 (en) 2014-01-16 2022-07-22 웨이브 라이프 사이언시스 리미티드 Chiral design
RU2708237C2 (en) 2014-08-22 2019-12-05 Общество с ограниченной ответственностью "НооГен" Modified oligonucleotides and method for production thereof
JP6689279B2 (en) 2014-12-16 2020-05-20 ロシュ イノベーション センター コペンハーゲン エーエス Chiral toxicity screening method
DK3234134T3 (en) 2014-12-17 2020-07-27 Proqr Therapeutics Ii Bv TARGETED RNA EDITING
US20180207197A1 (en) * 2015-06-26 2018-07-26 Kyowa Hakko Kirin Co., Ltd. Oligonucleotide derivative
MA43072A (en) 2015-07-22 2018-05-30 Wave Life Sciences Ltd COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
BR112018006636B1 (en) 2015-10-09 2023-03-28 Wave Life Sciences Ltd OLIGONUCLEOTIDE COMPOSITION, PHARMACEUTICAL COMPOSITION AND USE OF THE OLIGONUCLEOTIDE COMPOSITION
US20190070212A1 (en) * 2016-03-11 2019-03-07 Spring Bank Pharmaceuticals, Inc. Compounds and compositions for the treatment of infections
JP7286320B2 (en) 2016-03-13 2023-06-05 ウェイブ ライフ サイエンシズ リミテッド Compositions and methods for phosphoramidite and oligonucleotide synthesis
KR102522059B1 (en) 2016-04-18 2023-04-14 사렙타 쎄러퓨틱스 인코퍼레이티드 Antisense oligomers and methods of their use to treat diseases associated with the acid alpha-glucosidase gene
EA201892467A1 (en) 2016-04-29 2019-05-31 Сарепта Терапьютикс, Инк. Oligonucleotide Analogues Aimed at Human LMna
MA45270A (en) 2016-05-04 2017-11-09 Wave Life Sciences Ltd COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
US11013757B2 (en) 2016-06-03 2021-05-25 Wave Life Sciences Ltd. Oligonucleotides, compositions and methods thereof
WO2017220751A1 (en) 2016-06-22 2017-12-28 Proqr Therapeutics Ii B.V. Single-stranded rna-editing oligonucleotides
EP3478697A1 (en) 2016-06-30 2019-05-08 Sarepta Therapeutics, Inc. Exon skipping oligomers for muscular dystrophy
CN109715202A (en) * 2016-07-15 2019-05-03 斯必乐维生物科学公司 For treating the compound, composition and method of disease
KR102530513B1 (en) * 2016-08-23 2023-05-08 다이서나 파마수이티컬, 인크. Compositions comprising reversibly modified oligonucleotides and uses thereof
CN110352244B (en) 2016-09-01 2023-03-21 ProQR治疗上市公司Ⅱ Chemically modified RNA editing single stranded oligonucleotides
CN110088113A (en) 2016-11-23 2019-08-02 波涛生命科学有限公司 Composition and method for phosphoramidite and oligonucleotide synthesis
JOP20170192A1 (en) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co Cyclic dinucleotide
KR102552428B1 (en) 2016-12-19 2023-07-06 사렙타 쎄러퓨틱스 인코퍼레이티드 Exon skipping oligomeric conjugates for dyskinesia
CN110337308B (en) 2016-12-19 2023-09-01 萨勒普塔医疗公司 Exon-skipping oligomer conjugates for muscular dystrophy
WO2018118662A1 (en) 2016-12-19 2018-06-28 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
EP3603648A4 (en) 2017-03-29 2020-12-30 Shionogi & Co., Ltd Complex of nucleic acid medicine and multibranched lipid
CN110475784A (en) * 2017-03-29 2019-11-19 罗氏创新中心哥本哈根有限公司 It is used to prepare the three-dimensional orthogonal protecting group for limiting phosphorothioate oligonucleotide
CN111050806A (en) 2017-06-02 2020-04-21 波涛生命科学有限公司 Oligonucleotide compositions and methods of use thereof
US11597927B2 (en) 2017-06-02 2023-03-07 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
JP7402696B2 (en) 2017-06-21 2023-12-21 ウェイブ ライフ サイエンシズ リミテッド Compounds, compositions, and methods for synthesis
EP3645546A4 (en) 2017-06-30 2021-12-01 Solstice Biologics, Ltd. Chiral phosphoramidite auxiliaries and methods of their use
JP2020534253A (en) 2017-08-08 2020-11-26 ウェーブ ライフ サイエンシーズ リミテッド Oligonucleotide composition and its method
KR20200052369A (en) 2017-09-18 2020-05-14 웨이브 라이프 사이언시스 리미티드 Oligonucleotide production technology
EA201991450A1 (en) 2017-09-22 2019-12-30 Сарепта Терапьютикс, Инк. OLIGOMER CONJUGATES FOR EXONISM SKIP IN MUSCULAR DYSTROPHY
WO2019067981A1 (en) 2017-09-28 2019-04-04 Sarepta Therapeutics, Inc. Combination therapies for treating muscular dystrophy
JP2020536057A (en) 2017-09-28 2020-12-10 サレプタ セラピューティクス， インコーポレイテッド Combination therapy to treat muscular dystrophy
EP3687547A1 (en) 2017-09-28 2020-08-05 Sarepta Therapeutics, Inc. Combination therapies for treating muscular dystrophy
CN107892710B (en) * 2017-10-10 2021-04-13 河北大学 Supported platinum complex oxidant easy to recycle and use and preparation method and application thereof
WO2019075357A1 (en) 2017-10-12 2019-04-18 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
US11555189B2 (en) 2017-10-18 2023-01-17 Sarepta Therapeutics, Inc. Antisense oligomer compounds
US10758629B2 (en) 2018-05-29 2020-09-01 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
EP4219717A3 (en) 2018-06-13 2023-12-20 Sarepta Therapeutics, Inc. Exon skipping oligomers for muscular dystrophy
TW202020153A (en) 2018-07-27 2020-06-01 美商薩羅塔治療公司 Exon skipping oligomers for muscular dystrophy
WO2020027225A1 (en) 2018-07-31 2020-02-06 ファイメクス株式会社 Heterocyclic compound
WO2020123574A1 (en) 2018-12-13 2020-06-18 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
WO2020143740A1 (en) * 2019-01-10 2020-07-16 南开大学 Cyclic dinucleotide prodrug molecule, preparation method therefor and application thereof
US20220193246A1 (en) 2019-04-18 2022-06-23 Sarepta Therapeutics, Inc. Compositions for treating muscular dystrophy
WO2021020585A1 (en) 2019-07-31 2021-02-04 ファイメクス株式会社 Heterocyclic compound
US20230149560A1 (en) 2020-04-20 2023-05-18 Massachusetts Institute Of Technology Lipid compositions for delivery of sting agonist compounds and uses thereof
EP4153747A2 (en) 2020-05-22 2023-03-29 Wave Life Sciences Ltd. Double stranded oligonucleotide compositions and methods relating thereto
TW202241454A (en) * 2021-02-01 2022-11-01 日商第一三共股份有限公司 Novel method for producing antibody-immunostimulator conjugate
CA3233242A1 (en) 2021-09-30 2023-04-06 Sarepta Therapeutics, Inc. Antisense oligonucleotides having one or more abasic units
WO2023152371A1 (en) 2022-02-14 2023-08-17 Proqr Therapeutics Ii B.V. Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
WO2024013360A1 (en) 2022-07-15 2024-01-18 Proqr Therapeutics Ii B.V. Chemically modified oligonucleotides for adar-mediated rna editing
WO2024013361A1 (en) 2022-07-15 2024-01-18 Proqr Therapeutics Ii B.V. Oligonucleotides for adar-mediated rna editing and use thereof
WO2024064237A2 (en) 2022-09-21 2024-03-28 Sarepta Therapeutics, Inc. Dmd antisense oligonucleotide-mediated exon skipping efficiency

Family Cites Families (687)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2878264A (en) 1959-03-17 Substituted amino alcohols
CH372667A (en) 1957-09-26 1963-10-31 Robins Co Inc A H Process for the preparation of 3-aryl-3-pyrrolidinols
US3135766A (en) 1961-10-03 1964-06-02 Mead Johnson & Co 3-substituted-3-pyrrolidinols
US3484473A (en) 1967-05-12 1969-12-16 Buckman Labor Inc Methylene bisesters of thiolsulfonic acids
DE1934150A1 (en) 1968-07-10 1970-01-15 Pennwalt Corp New 1-alkanoyloxy-1,2,4,5-tetrahydro-3H, 3-benzazepine
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US3745162A (en) 1970-08-31 1973-07-10 Robins Co Inc A H 1,2,3,4-tetrahydroisoquinoline-2-(thio)-carboxamides
GB1448437A (en) 1973-02-24 1976-09-08 Beecham Group Ltd Diphenylpropylamines
US4022791A (en) 1975-06-03 1977-05-10 Pfizer Inc. 2-Aminomethyl-3,4-dihydronaphthalenes
GB1504424A (en) 1975-08-09 1978-03-22 Beecham Group Ltd Isoquinoline-derived aminoethers
BR7807288A (en) 1977-11-08 1979-06-12 Genentech Inc POLYNUCLEOTIDE SYNTHESIS PROCESS
DD133885B1 (en) 1978-01-04 1981-02-25 Hans Lehmann AGENTS FOR THE CONTROL OF PHYTOPATHOGENIC BACTERIA AND MUSHROOMS
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4542142A (en) 1982-11-22 1985-09-17 Roussel Uclaf Insecticidal cyclopropane carboxylic acid derivatives with 3-unsaturated-side chain
DE3329892A1 (en) 1983-08-18 1985-03-07 Köster, Hubert, Prof. Dr., 2000 Hamburg METHOD FOR PRODUCING OLIGONUCLEOTIDES
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
US5643889A (en) * 1984-07-11 1997-07-01 Temple University-Of The Commonwealth System Of Pennsylvania Cholesterol conjugates of 2'5'-oligoadenylate derivatives and antiviral uses thereof
FR2567892B1 (en) 1984-07-19 1989-02-17 Centre Nat Rech Scient NOVEL OLIGONUCLEOTIDES, THEIR PREPARATION PROCESS AND THEIR APPLICATIONS AS MEDIATORS IN DEVELOPING THE EFFECTS OF INTERFERONS
US5367066A (en) 1984-10-16 1994-11-22 Chiron Corporation Oligonucleotides with selectably cleavable and/or abasic sites
FR2575751B1 (en) 1985-01-08 1987-04-03 Pasteur Institut NOVEL ADENOSINE DERIVATIVE NUCLEOSIDES, THEIR PREPARATION AND THEIR BIOLOGICAL APPLICATIONS
FR2576898B1 (en) 1985-02-01 1988-01-08 Lafon Labor 3-PHENYL-TETRAHYDROPYRIDINE DERIVATIVES, METHOD OF PREPARATION AND THERAPEUTIC USE
JPH0658512B2 (en) 1985-04-12 1994-08-03 富士写真フイルム株式会社 Silver halide photographic light-sensitive material
US4659774A (en) 1985-11-01 1987-04-21 American Hoechst Corporation Support for solid-phase oligonucleotide synthesis
US4735949A (en) 1986-02-18 1988-04-05 Warner-Lambert Company Disubstituted-7-pyrrolidinonaphthyridine antibacterial agents
US4840956A (en) 1986-02-18 1989-06-20 Warner-Lambert Company Novel disubstituted-7-pyrrolidinoquinoline antibacterial agents
IL83663A0 (en) 1986-10-27 1988-01-31 Robins Co Inc A H Preparation of 3-pyrrolidinols
AU598946B2 (en) 1987-06-24 1990-07-05 Howard Florey Institute Of Experimental Physiology And Medicine Nucleoside derivatives
DE3884517T2 (en) 1987-07-30 1994-02-10 Univ Bar Ilan Biologically active carboxylic acid esters.
US4923901A (en) 1987-09-04 1990-05-08 Millipore Corporation Membranes with bound oligonucleotides and peptides
US5175273A (en) 1988-07-01 1992-12-29 Genentech, Inc. Nucleic acid intercalating agents
US4945158A (en) 1988-08-12 1990-07-31 American Cyanamid Company Antidiabetic phosphonates
US4943629A (en) 1988-08-12 1990-07-24 American Cyanamid Company Antidiabetic alpha-substituted phosphonates
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
JP2794461B2 (en) 1989-08-17 1998-09-03 有機合成薬品工業株式会社 Phosphoramidite compounds and solid-phase synthesis of oligoribonucleotides using the same
US5141813A (en) 1989-08-28 1992-08-25 Clontech Laboratories, Inc. Multifunctional controlled pore glass reagent for solid phase oligonucleotide synthesis
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
CA2029273A1 (en) 1989-12-04 1991-06-05 Christine L. Brakel Modified nucleotide compounds
JPH05503517A (en) 1989-12-18 1993-06-10 バージニア・コモンウェルス・ユニバーシティ Sigma receptor ligand and its uses
US5130302A (en) 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US5212295A (en) 1990-01-11 1993-05-18 Isis Pharmaceuticals Monomers for preparation of oligonucleotides having chiral phosphorus linkages
US5914396A (en) 1990-01-11 1999-06-22 Isis Pharmaceuticals, Inc. 2'-O-modified nucleosides and phosphoramidites
US5620963A (en) 1991-10-15 1997-04-15 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating protein kinase C having phosphorothioate linkages of high chiral purity
US5587470A (en) 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. 3-deazapurines
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US5635488A (en) 1991-10-15 1997-06-03 Isis Pharmaceuticals, Inc. Compounds having phosphorodithioate linkages of high chiral purity
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5457191A (en) 1990-01-11 1995-10-10 Isis Pharmaceuticals, Inc. 3-deazapurines
US5852188A (en) 1990-01-11 1998-12-22 Isis Pharmaceuticals, Inc. Oligonucleotides having chiral phosphorus linkages
US5506212A (en) 1990-01-11 1996-04-09 Isis Pharmaceuticals, Inc. Oligonucleotides with substantially chirally pure phosphorothioate linkages
US6339066B1 (en) 1990-01-11 2002-01-15 Isis Pharmaceuticals, Inc. Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C
EP1418179A3 (en) 1990-01-11 2006-03-08 Isis Pharmaceuticals, Inc. Compositions and methods for detecting and modulating rna activity and gene expression
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US5292875A (en) 1990-04-20 1994-03-08 Lynx Therapeutics, Inc. Method of synthesizing sulfurized oligonucleotide analogs
ES2139578T3 (en) 1990-05-23 2000-02-16 Isis Pharmaceuticals Inc COMPOSITIONS AND PROCEDURE FOR MODULATING RNA ACTIVITY THROUGH MODIFICATION OF THE 5 'PROTECTIVE STRUCTURE OF RNA.
US5541307A (en) 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5834607A (en) 1990-07-27 1998-11-10 Isis Pharmaceuticals, Inc. Amines and methods of making and using the same
US5998603A (en) 1994-09-29 1999-12-07 Isis Pharmaceuticals, Inc. 4'-desmethyl nucleoside analogs, and oligomers thereof
US5783682A (en) 1990-07-27 1998-07-21 Isis Pharmaceuticals, Inc. Oligonucleotide mimics having nitrogen-containing linkages
US5223618A (en) 1990-08-13 1993-06-29 Isis Pharmaceuticals, Inc. 4'-desmethyl nucleoside analog compounds
US5688941A (en) 1990-07-27 1997-11-18 Isis Pharmaceuticals, Inc. Methods of making conjugated 4' desmethyl nucleoside analog compounds
US5386023A (en) 1990-07-27 1995-01-31 Isis Pharmaceuticals Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
US5618704A (en) 1990-07-27 1997-04-08 Isis Pharmacueticals, Inc. Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5138045A (en) 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
WO1994022886A1 (en) 1993-03-30 1994-10-13 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
US6087482A (en) 1990-07-27 2000-07-11 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5677437A (en) 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
WO1992002258A1 (en) 1990-07-27 1992-02-20 Isis Pharmaceuticals, Inc. Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
US6121433A (en) 1990-07-27 2000-09-19 Isis Pharmaceuticals, Inc. Oligomeric compounds having nitrogen-containing linkages
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5792844A (en) 1990-07-27 1998-08-11 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent nitrogen atoms
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
JPH04348044A (en) 1991-02-21 1992-12-03 Matsushita Electron Corp Resin sealing device for semiconductor
US5512668A (en) 1991-03-06 1996-04-30 Polish Academy Of Sciences Solid phase oligonucleotide synthesis using phospholane intermediates
US20020183502A1 (en) 1991-05-21 2002-12-05 Mesmaeker Alain De Backbone-modified oligonucleotide analogs and methods for using same
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US6414112B1 (en) 1991-05-24 2002-07-02 Ole Buchardt Peptide nucleic acids having 2,6-diaminopurine nucleobases
JPH04348077A (en) 1991-05-24 1992-12-03 Nec Corp Thin-film transistor
US6538126B1 (en) 1991-06-10 2003-03-25 Lucky Limited Hepatitis C diagnostics and vaccines
US5359052A (en) 1991-08-05 1994-10-25 Polish Academy Of Sciences Chalcophospholanes useful in the synthesis of oligonucleoside phosphorothioates, phosphorodithioates and related selenates
US5646267A (en) 1991-08-05 1997-07-08 Polish Academy Of Sciences Method of making oligonucleotides and oligonucleotide analogs using phospholanes and enantiomerically resolved phospholane analogues
US6369209B1 (en) 1999-05-03 2002-04-09 Isis Pharmaceuticals, Inc. Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US7119184B2 (en) 1991-08-12 2006-10-10 Isis Pharmaceuticals, Inc. Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US5661134A (en) 1991-10-15 1997-08-26 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity
US5576302A (en) 1991-10-15 1996-11-19 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity
US5607923A (en) 1991-10-15 1997-03-04 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity
WO1993008296A1 (en) 1991-10-15 1993-04-29 Isis Pharmaceuticals, Inc. Oligonucleotides having chiral phosphorus linkages
US5599797A (en) 1991-10-15 1997-02-04 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5654284A (en) 1991-10-15 1997-08-05 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating RAF kinase having phosphorothioate linkages of high chiral purity
ES2103918T3 (en) 1991-10-17 1997-10-01 Ciba Geigy Ag BICYCLE NUCLEOSIDES, OLIGONUCLEOTIDES, PROCEDURE FOR THEIR OBTAINING AND INTERMEDIATE PRODUCTS.
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
US6235887B1 (en) 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
CA2126691C (en) 1991-12-24 2003-05-06 Phillip Dan Cook Gapped 2' modified oligonucleotides
GB9213601D0 (en) 1992-06-26 1992-08-12 Mastico Robert A Protein based delivery system
US7067497B2 (en) 1992-09-29 2006-06-27 Isis Pharmaceuticals, Inc. Modulation of telomere length by oligonucleotides having a G-core sequence
US6444656B1 (en) 1992-12-23 2002-09-03 Biochem Pharma, Inc. Antiviral phosphonate nucleotides
US6005107A (en) 1992-12-23 1999-12-21 Biochem Pharma, Inc. Antiviral compounds
KR960701077A (en) 1993-01-25 1996-02-24 다알렌 반스톤 Oligonucleotide Alkylphosphonate and Alkylphosphonothioate (ALIGLPHOSPHONATES AND ALKYLPHOSPHONOTHIOATES)
JPH08508490A (en) 1993-03-31 1996-09-10 スターリング ウィンスロップ インコーポレイティド Novel 5'-substituted nucleosides and oligomers obtained therefrom
AU6551094A (en) 1993-03-31 1994-10-24 Sterling Winthrop Inc. Bifunctional nucleosides, oligomers thereof, and methods of making and using the same
US5955591A (en) 1993-05-12 1999-09-21 Imbach; Jean-Louis Phosphotriester oligonucleotides, amidites and method of preparation
US6015886A (en) 1993-05-24 2000-01-18 Chemgenes Corporation Oligonucleotide phosphate esters
DE69412704T2 (en) 1993-06-10 1999-02-04 Idemitsu Petrochemical Co Injection mold
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5643989A (en) 1993-10-29 1997-07-01 Azdel, Inc. Fiber reinforced functionalized polyolefin composites
US5457187A (en) 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
DE4435728A1 (en) 1994-01-19 1995-07-20 Boehringer Mannheim Gmbh Biotin silane compounds and binding matrix containing these compounds
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
WO1995022615A1 (en) 1994-02-22 1995-08-24 Novo Nordisk A/S A method of preparing a variant of a lipolytic enzyme
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
RU2215034C2 (en) 1994-05-11 2003-10-27 Новосимс А/С ENZYME WITH ACTIVITY OF ENDO-1,3(4)-β-GLUCANASE, DNA ENCODING ITS AND METHOD FOR ITS PREPARING
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
HRP950288A2 (en) 1994-05-31 1997-08-31 Bayer Ag Oxalylamino-benzofuran- and benzothienyl-derivatives
DK0685475T3 (en) 1994-05-31 1999-08-30 Bayer Ag Amino-benzofuryl and thienyl derivatives
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ATE202569T1 (en) 1994-09-07 2001-07-15 Hybridon Inc PRODRUG OLIGONUCLEOTIDES
US5681940A (en) 1994-11-02 1997-10-28 Icn Pharmaceuticals Sugar modified nucleosides and oligonucleotides
EP0807171A1 (en) 1994-12-22 1997-11-19 HYBRIDON, Inc. Synthesis of stereospecific oligonucleotide phosphorothioates
GB9501465D0 (en) 1995-01-25 1995-03-15 King S College London Nucleoside phosphorothioate derivatives,synthesis and use thereof
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
AU5359496A (en) 1995-03-06 1996-09-23 Isis Pharmaceuticals, Inc. Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom
EP0739983B1 (en) 1995-04-27 2009-12-30 Takara Bio Inc. Gene encoding lacto-n-biosidase
CA2220433C (en) 1995-05-11 2010-02-16 Applied Research Systems Ars Holding N.V. Il-6 activity inhibitor
EP0828729A1 (en) 1995-05-19 1998-03-18 Glycomed Incorporated Collection of activated glycoside compounds and their biological use
AU5871196A (en) 1995-05-23 1996-12-24 Hybridon, Inc. Methods and compounds for the synthesis of oligonucleotides and the oligonucleotides thereby produced
DK0836612T3 (en) 1995-05-23 2000-10-30 Hybridon Inc New synthons for stereoselective oligonucleotide synthesis
EP0831854A4 (en) 1995-06-06 2001-01-24 Isis Pharmaceuticals Inc Oligonucleotides having phosphorothioate linkages of high chiral purity
US5932450A (en) 1995-06-07 1999-08-03 Gen-Probe Incorporated Enzymatic synthesis of oligonucleotides using digestible templates
EP0759470B1 (en) 1995-06-29 2006-10-25 Takara Bio Inc. Gene encoding endoglycoceramidase activator
US5795765A (en) 1995-06-29 1998-08-18 Takara Shuzo Co., Ltd. Gene encoding endoglycoceramidase
US6017700A (en) 1995-08-04 2000-01-25 Bayer Corporation Cationic oligonucleotides, and related methods of synthesis and use
US5936080A (en) 1996-05-24 1999-08-10 Genta Incorporated Compositions and methods for the synthesis of organophosphorus derivatives
WO1997009443A1 (en) 1995-09-05 1997-03-13 Michigan State University PROCESS FOR THE ISOLATION AND PURIFICATION OF TAXOL AND TAXANES FROM TAXUS spp
US6476216B1 (en) 1995-10-20 2002-11-05 Mcgill University Preparation of phosphorothioate oligomers
US5734041A (en) 1995-10-20 1998-03-31 Mcgill University Preparation of chiral phosphorothioate oligomers
US6160109A (en) 1995-10-20 2000-12-12 Isis Pharmaceuticals, Inc. Preparation of phosphorothioate and boranophosphate oligomers
US7018793B1 (en) 1995-12-07 2006-03-28 Diversa Corporation Combinatorial screening of mixed populations of organisms
WO1997029757A1 (en) 1996-02-15 1997-08-21 National Institutes Of Health Rnase l activators and antisense oligonucleotides effective to treat rsv infections
US6214805B1 (en) 1996-02-15 2001-04-10 The United States Of America As Represented By The Department Of Health And Human Services RNase L activators and antisense oligonucleotides effective to treat RSV infections
GB9604669D0 (en) 1996-03-05 1996-05-01 Ciba Geigy Ag Chemical compounds
US5824669A (en) 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
DK0898618T3 (en) 1996-05-10 2008-02-25 Novozymes As Method for providing novel DNA sequences
US5856465A (en) 1996-05-24 1999-01-05 Polska Akademia Nauk Centrum Badan Molekularnych I Makromolekularnych Compositions and methods for the synthesis of chirally pure organophosphorus nucleoside derivatives
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
DE19622783A1 (en) 1996-06-07 1997-12-11 Hoechst Ag Isolation of the biosynthetic genes for pseudo-oligosaccharides from Streptomyces glaucescens GLA.O and their use
JP2000514307A (en) 1996-07-16 2000-10-31 ジェン―プローブ・インコーポレーテッド Methods for detecting and amplifying nucleic acid sequences using modified oligonucleotides with increased target specific T <M>
AU717387B2 (en) 1996-07-24 2000-03-23 Rolf H. Berg Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
WO1998007734A1 (en) * 1996-08-21 1998-02-26 Hybridon, Inc. Oligonucleotide prodrugs
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
GB9621522D0 (en) 1996-10-16 1996-12-04 Biocompatibles Ltd Synthesis of phosphorus compounds
US6172209B1 (en) 1997-02-14 2001-01-09 Isis Pharmaceuticals Inc. Aminooxy-modified oligonucleotides and methods for making same
US6639062B2 (en) 1997-02-14 2003-10-28 Isis Pharmaceuticals, Inc. Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom
US6369237B1 (en) 1997-03-07 2002-04-09 President And Fellows Of Harvard College DNA glycosylase inhibitors, and uses related thereto
US6015887A (en) 1997-04-11 2000-01-18 Isis Pharmaceuticals, Inc. Chiral peptide nucleic acids and methods for preparing same
US6468983B2 (en) 1997-04-21 2002-10-22 The Cleveland Clinic Foundation RNase L activators and antisense oligonucleotides effective to treat telomerase-expressing malignancies
PL184612B1 (en) 1997-04-25 2002-11-29 Pan Method of obtaining p-chiral analoques of nucleotides
CA2291839A1 (en) 1997-05-28 1998-12-03 Peter E. Nielsen Conjugated peptide nucleic acids having enhanced cellular uptake
EP0991635A1 (en) 1997-06-27 2000-04-12 The Procter & Gamble Company Pro-fragrance cyclic acetals
WO1999005160A2 (en) 1997-07-25 1999-02-04 Hybridon, Inc. Oligonuclotides having 3' terminal stereospecific phosphorothioates
US6767739B2 (en) 2001-07-30 2004-07-27 Isis Pharmaceuticals Inc. Antisense modulation of microsomal triglyceride transfer protein expression
GB9717158D0 (en) 1997-08-13 1997-10-22 King S College London Solution synthesis of oligonucleotides and their phosphorothioate analogues
US6383808B1 (en) 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
US6750344B1 (en) 1997-09-05 2004-06-15 Isis Pharmaceuticals, Inc. Amine compounds and combinatorial libraries comprising same
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
DE19741715A1 (en) 1997-09-22 1999-03-25 Hoechst Ag New pentopyranosyl nucleoside compounds
US6232463B1 (en) 1997-10-09 2001-05-15 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US6617438B1 (en) 1997-11-05 2003-09-09 Sirna Therapeutics, Inc. Oligoribonucleotides with enzymatic activity
US6528640B1 (en) 1997-11-05 2003-03-04 Ribozyme Pharmaceuticals, Incorporated Synthetic ribonucleic acids with RNAse activity
US6080543A (en) 1997-12-08 2000-06-27 E. & J. Gallo Winery Detection of fungal pathogens
US6582936B1 (en) 1997-12-12 2003-06-24 The Regents Of The University Of California Methods for making nucleic acids
US6248519B1 (en) 1998-03-11 2001-06-19 E & J Gallo Winery Detection of fermentation-related microorganisms
US7045610B2 (en) 1998-04-03 2006-05-16 Epoch Biosciences, Inc. Modified oligonucleotides for mismatch discrimination
AU3884199A (en) 1998-05-06 1999-11-23 Ottawa Health Research Institute Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
IL139646A0 (en) 1998-05-14 2002-02-10 Coley Pharm Group Inc Methods for regulating hematopoiesis using cpg-oligonucleotides
US6242589B1 (en) 1998-07-14 2001-06-05 Isis Pharmaceuticals, Inc. Phosphorothioate oligonucleotides having modified internucleoside linkages
US6867294B1 (en) 1998-07-14 2005-03-15 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
JP2002521489A (en) 1998-07-27 2002-07-16 ユニバーシティ オブ アイオワ リサーチ ファウンデーション Stereoisomers of CpG oligonucleotides and related methods
PT1104306E (en) 1998-08-10 2006-05-31 Antigenics Inc CPG COMPOSITIONS AND SAPONIN ADJUVANTS AND THEIR METHODS
WO2000023444A1 (en) 1998-10-21 2000-04-27 Abbott Laboratories 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
US6995259B1 (en) 1998-10-23 2006-02-07 Sirna Therapeutics, Inc. Method for the chemical synthesis of oligonucleotides
US6451524B1 (en) 1998-11-25 2002-09-17 Isis Pharmaceuticals, Inc. Identification of disease predictive nucleic acids
WO2000031110A1 (en) 1998-11-25 2000-06-02 Isis Pharmaceuticals, Inc. Identification of disease predictive nucleic acids
US6379942B1 (en) 1998-12-21 2002-04-30 Genencor International, Inc. Chemically modified enzymes with multiple charged variants
WO2000040749A2 (en) 1999-01-06 2000-07-13 Genenews Inc. Method for the detection of gene transcripts in blood and uses thereof
US6265172B1 (en) 1999-02-08 2001-07-24 University Of Kentucky Diagnostic test and therapy for manganese superoxide dismutate (mNsod) associated diseases
US6121437A (en) 1999-03-16 2000-09-19 Isis Pharmaceuticals, Inc. Phosphate and thiophosphate protecting groups
US6506594B1 (en) 1999-03-19 2003-01-14 Cornell Res Foundation Inc Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
GB9907245D0 (en) 1999-03-29 1999-05-26 Goldsborough Andrew Cleavage of nucleic acids from solid supports
JP3072345B1 (en) 1999-03-31 2000-07-31 農林水産省家畜衛生試験場長 Swine erysipelas recombinant subunit vaccine
US5998148A (en) 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US6300069B1 (en) 1999-05-03 2001-10-09 Qiagen Gmbh Generation and amplification of nucleic acids from ribonucleic acids
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
US6271004B1 (en) 1999-06-25 2001-08-07 Display Systems Biotech A/S Method for improved reverse transcription at high temperatures
US6066500A (en) 1999-06-25 2000-05-23 Isis Pharmaceuticals Inc. Antisense modulation of Beta catenin expression
US6414135B1 (en) 1999-07-07 2002-07-02 Isis Pharmaceuticals, Inc. C3′-methylene hydrogen phosphonate monomers and related compounds
US20030092647A1 (en) 2001-08-08 2003-05-15 Crooke Rosanne M. Antisense modulation of cholesteryl ester transfer protein expression
US6147200A (en) 1999-08-19 2000-11-14 Isis Pharmaceuticals, Inc. 2'-O-acetamido modified monomers and oligomers
US7264932B2 (en) 1999-09-24 2007-09-04 Applera Corporation Nuclease inhibitor cocktail
CN1454091A (en) 1999-09-25 2003-11-05 衣阿华大学研究基金会 Immunostimulatory nucleic acids
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
WO2001022990A2 (en) 1999-09-27 2001-04-05 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
US20020082227A1 (en) 1999-09-30 2002-06-27 Scott Henry Use of oligonucleotides for inhibition of complement activation
AU7863200A (en) 1999-10-06 2001-05-10 Quark Biotech, Inc. Method for enrichment of natural antisense messenger rna
GB9924285D0 (en) 1999-10-14 1999-12-15 Avecia Ltd Process
US20010055761A1 (en) 1999-10-29 2001-12-27 Agilent Technologies Small scale dna synthesis using polymeric solid support with functionalized regions
FR2800750B1 (en) 1999-11-05 2003-01-31 Centre Nat Rech Scient MEMBRANE PROTEINS CTL (CHOLINE TRANSPORTER LIKE) INVOLVED IN THE TRANSPORT OF CHOLINE
AU1656601A (en) 1999-11-12 2001-06-12 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6322985B1 (en) 1999-12-27 2001-11-27 Technion Research And Development Foundation Ltd. Abundant, well distributed and hyperpolymorphic simple sequence repeats in prokaryote genomes and use of same for prokaryote classification and typing
US7501091B2 (en) 1999-12-30 2009-03-10 Smiths Detection Inc. Sensors with improved properties
WO2001050349A1 (en) 1999-12-30 2001-07-12 Rutgers, The State University Of New Jersey Electronic document customization and transformation utilizing user feedback
US6649750B1 (en) 2000-01-05 2003-11-18 Isis Pharmaceuticals, Inc. Process for the preparation of oligonucleotide compounds
US6159697A (en) 2000-01-19 2000-12-12 Isis Pharmaceuticals, Inc. Antisense modulation of Smad7 expression
US7585847B2 (en) 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US6495677B1 (en) 2000-02-15 2002-12-17 Kanda S. Ramasamy Nucleoside compounds
GB0004889D0 (en) 2000-03-01 2000-04-19 Avecia Ltd Synthesis of oligonucleotides
US6936432B2 (en) 2000-03-01 2005-08-30 Message Pharmaceuticals Bacterial RNase P proteins and their use in identifying antibacterial compounds
US6649172B2 (en) 2000-03-17 2003-11-18 Corixa Corporation Amphipathic aldehydes and their uses as adjuvants and immunoeffectors
JP4219590B2 (en) 2000-04-20 2009-02-04 エフ．ホフマン−ラ ロシュ アーゲー Pyrrolidine and piperidine derivatives and their use for the treatment of neurodegenerative disorders
DE10019756A1 (en) 2000-04-20 2001-10-25 Bayer Ag Process for the production of superabsorbent polymers from polyacrylonitriles
WO2001085751A1 (en) * 2000-05-09 2001-11-15 Reliable Biopharmaceutical, Inc. Polymeric compounds useful as prodrugs
US6492171B2 (en) 2000-05-16 2002-12-10 Isis Pharmaceuticals, Inc. Antisense modulation of TERT expression
US6815542B2 (en) 2000-06-16 2004-11-09 Ribapharm, Inc. Nucleoside compounds and uses thereof
CA2416631C (en) 2000-08-03 2011-11-22 F. Hoffmann-La Roche Ag Nucleic acid binding compounds containing pyrazolo[3,4-d]pyrimidine analogues of purin-2,6-diamine and their uses
US6725412B1 (en) 2000-08-15 2004-04-20 Dolby Laboratories Licensing Corporation Low latency data encoder
US6809195B1 (en) 2000-08-16 2004-10-26 Isis Pharmaceuticals, Inc. Process for the preparation of oligonucleotides
US6559279B1 (en) 2000-09-08 2003-05-06 Isis Pharmaceuticals, Inc. Process for preparing peptide derivatized oligomeric compounds
JP2005500806A (en) 2000-09-15 2005-01-13 コーリー ファーマシューティカル ゲーエムベーハー Process for high-throughput screening of immune agonist / immunoantagonists based on CpG
EP1191097A1 (en) 2000-09-21 2002-03-27 Leids Universitair Medisch Centrum Induction of exon skipping in eukaryotic cells
GB0024752D0 (en) 2000-10-10 2000-11-22 Univ Belfast Oxidative halogenation of aromatic compounds
MXPA03003408A (en) 2000-10-18 2005-06-30 Glaxosmithkline Biolog Sa Vaccines.
US6372492B1 (en) 2000-10-30 2002-04-16 Isis Pharmaceuticals, Inc. Antisense modulation of talin expression
US6682889B1 (en) 2000-11-08 2004-01-27 Becton, Dickinson And Company Amplification and detection of organisms of the Chlamydiaceae family
NL1016978C2 (en) 2000-12-22 2002-06-25 Robert Jan Colenbrander Device and method for packaging and preparing food and method for manufacturing such a device.
SI1355916T1 (en) 2001-01-22 2007-04-30 Merck & Co Inc Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
ATE501251T1 (en) 2001-01-25 2011-03-15 Evolva Ltd CELL LIBRARY
US8008459B2 (en) 2001-01-25 2011-08-30 Evolva Sa Concatemers of differentially expressed multiple genes
WO2002059294A1 (en) 2001-01-26 2002-08-01 Commonwealth Scientific And Industrial Research O Rganisation Methods and means for producing efficient silencing construct using recombinational cloning
US20050277133A1 (en) 2001-05-18 2005-12-15 Sirna Therapeutics, Inc. RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
WO2002097134A2 (en) 2001-05-25 2002-12-05 Isis Pharmaceuticals, Inc. Modified peptide nucleic acid
GB0113523D0 (en) 2001-06-04 2001-07-25 Torotrak Dev Ltd An Hydraulic control circuit for a continuosly variable transmission
US20030069410A1 (en) 2001-06-14 2003-04-10 Isis Pharmaceuticals, Inc. Methods for preparing oligonucleotides having chiral phosphorothioate linkages
US20050019915A1 (en) 2001-06-21 2005-01-27 Bennett C. Frank Antisense modulation of superoxide dismutase 1, soluble expression
NZ530632A (en) 2001-06-29 2007-04-27 Chiron Corp HCV E1E2 vaccine compositions comprising E1E2 antigens, submicron oil-in-water emulsions and/or CpG oligonucleotides
CA2452458A1 (en) 2001-07-03 2003-01-16 Isis Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
US7205399B1 (en) 2001-07-06 2007-04-17 Sirna Therapeutics, Inc. Methods and reagents for oligonucleotide synthesis
US6440739B1 (en) 2001-07-17 2002-08-27 Isis Pharmaceuticals, Inc. Antisense modulation of glioma-associated oncogene-2 expression
US7425545B2 (en) 2001-07-25 2008-09-16 Isis Pharmaceuticals, Inc. Modulation of C-reactive protein expression
US7888324B2 (en) 2001-08-01 2011-02-15 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US6455308B1 (en) 2001-08-01 2002-09-24 Isis Pharmaceuticals, Inc. Antisense modulation of serum amyloid A4 expression
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
US7259150B2 (en) 2001-08-07 2007-08-21 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein (a) expression
WO2003020884A2 (en) 2001-08-14 2003-03-13 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Method for rapid generation of mature dendritic cells
CA2458393A1 (en) 2001-08-24 2003-03-06 Massachusetts Institute Of Technology Reagents that facilitate the purification of compounds synthesized on a solid support
US7049122B2 (en) 2001-09-21 2006-05-23 Academia Sinica Mutant-type lipases and applications thereof
US6933288B2 (en) 2002-02-04 2005-08-23 Isis Pharmaceuticals, Inc. Pyranosyl cytosines: pharmaceutical formulations and methods
JP4348044B2 (en) 2002-02-12 2009-10-21 株式会社キラルジェン Method for producing highly stereoregular dinucleoside phosphorothioates
US20030159938A1 (en) 2002-02-15 2003-08-28 George Hradil Electroplating solution containing organic acid complexing agent
US20040149587A1 (en) 2002-02-15 2004-08-05 George Hradil Electroplating solution containing organic acid complexing agent
US20050096284A1 (en) 2002-02-20 2005-05-05 Sirna Therapeutics, Inc. RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
US8232383B2 (en) 2002-02-20 2012-07-31 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003213628A1 (en) 2002-02-28 2003-09-16 Biota, Inc. Nucleoside 5'-monophosphate mimics and their prodrugs
US7285658B2 (en) 2002-02-28 2007-10-23 Biota, Inc. Nucleotide mimics and their prodrugs
US7288376B2 (en) 2002-03-22 2007-10-30 Council Of Scientific And Industrial Research Method of detection of SP-A2 gene variants useful for prediction of predisposition to aspergillosis
US20040102394A1 (en) 2002-11-23 2004-05-27 Isis Pharmaceuticals Inc. Modulation of huntingtin interacting protein 2 expression
US7247621B2 (en) 2002-04-30 2007-07-24 Valeant Research & Development Antiviral phosphonate compounds and methods therefor
WO2003097662A1 (en) 2002-05-15 2003-11-27 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein b expression
AU2003241621A1 (en) 2002-05-24 2003-12-12 Isis Pharmaceuticals, Inc. Oligonucleotides having modified nucleoside units
WO2003099840A1 (en) 2002-05-24 2003-12-04 Isis Pharmaceuticals, Inc. Oligonucleotides having modified nucleoside units
US7507808B2 (en) 2002-12-12 2009-03-24 Isis Pharmaceuticals, Inc. Modulation of endothelial lipase expression
AU2003248708A1 (en) 2002-06-17 2003-12-31 Isis Pharmaceuticals, Inc. Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation
BR0311995A (en) 2002-06-20 2005-04-05 Cytos Biotechnology Ag Virus-like particles packaged for use as adjuvants: Method of preparation and use
WO2004003228A1 (en) 2002-07-01 2004-01-08 Unisearch Limited Genotyping method
EP2333062A1 (en) 2002-07-10 2011-06-15 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. RNA-interference by single-stranded RNA molecules
US20040023905A1 (en) 2002-07-31 2004-02-05 Isis Pharmaceuticals Inc. Antisense modulation of LAR expression
US20050042646A1 (en) 2002-08-05 2005-02-24 Davidson Beverly L. RNA interference suppresion of neurodegenerative diseases and methods of use thereof
US20080274989A1 (en) 2002-08-05 2008-11-06 University Of Iowa Research Foundation Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
US20050255086A1 (en) 2002-08-05 2005-11-17 Davidson Beverly L Nucleic acid silencing of Huntington's Disease gene
WO2004014933A1 (en) 2002-08-07 2004-02-19 University Of Massachusetts Compositions for rna interference and methods of use thereof
AU2003259735A1 (en) 2002-08-08 2004-02-25 Sirna Therapeutics, Inc. Small-mer compositions and methods of use
AR040996A1 (en) 2002-08-19 2005-04-27 Coley Pharm Group Inc IMMUNE STIMULATING NUCLEIC ACIDS
US7414116B2 (en) 2002-08-23 2008-08-19 Illumina Cambridge Limited Labelled nucleotides
BR0314236A (en) 2002-09-13 2005-08-09 Replicor Inc Oligonucleotide formulation, pharmaceutical composition, kit, antiviral compound, preparation of oligonucleotide and methods for selection of an antiviral oligonucleotide for use as an antiviral agent, for prophylaxis or treatment of a viral infection in a patient, for prophylactic treatment of cancer caused by oncoviruses. for identifying a compound that alters the binding of an oligonucleotide to at least one viral component, for purifying oligonucleotide binding to at least one viral component and for enriching oligonucleotides from an oligonucleotide cluster
US7030230B2 (en) 2002-10-25 2006-04-18 Isis Pharmaceuticals, Inc. Process of purifying phosphoramidites
SI2241325T1 (en) 2002-10-29 2012-05-31 Coley Pharm Group Inc Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
AU2003286808A1 (en) 2002-11-01 2004-06-07 The Regents Of The University Of Colorado Dopamine neurons from human embryonic stem cells
WO2004044136A2 (en) 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2’-modified nucleosides for use in gene modulation
WO2004041889A2 (en) 2002-11-05 2004-05-21 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
AU2003291721A1 (en) 2002-11-05 2004-06-03 Isis Pharmaceuticals, Inc. Phosphorous-linked oligomeric compounds and their use in gene modulation
CA2505090A1 (en) 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. Conjugated oligomeric compounds and their use in gene modulation
US7381527B2 (en) 2002-11-06 2008-06-03 Council Of Scientific And Industrial Research Method of detection of SP-A2 gene variants
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
EP2336318B1 (en) 2002-11-13 2013-04-24 Genzyme Corporation Antisense modulation of apolipoprotein b expression
EP2305812A3 (en) 2002-11-14 2012-06-06 Dharmacon, Inc. Fuctional and hyperfunctional sirna
EP1605978B1 (en) 2003-03-07 2010-09-01 Alnylam Pharmaceuticals Inc. Therapeutic compositions
WO2004080466A1 (en) 2003-03-07 2004-09-23 Ribapharm Inc. Cytidine analogs and methods of use
AU2003225410A1 (en) 2003-03-21 2004-10-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
GB0306657D0 (en) 2003-03-24 2003-04-30 Avecia Ltd Process and compounds
NZ542323A (en) 2003-03-26 2008-07-31 Cytos Biotechnology Ag Melan-A peptide analogue-virus-like-particle conjugates
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
ITRM20030149A1 (en) 2003-04-02 2004-10-03 Giuliani Spa ANTISENSE OLIGONUCLEOTIDES (ODN) FOR SMAD7 AND THEIR USE IN THE MEDICAL FIELD
US7598227B2 (en) 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
WO2004096233A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Nucleoside phosphonate conjugates
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
US20090247488A1 (en) 2003-04-25 2009-10-01 Carina Cannizzaro Anti-inflammatory phosphonate compounds
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
KR20060061930A (en) 2003-04-25 2006-06-08 길리애드 사이언시즈, 인코포레이티드 Anti-cancer phosphonate analogues
PT1628685E (en) 2003-04-25 2011-03-16 Gilead Sciences Inc Antiviral phosphonate analogs
US20050261237A1 (en) 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
CN101410120A (en) 2003-04-25 2009-04-15 吉里德科学公司 Anti-inflammatory phosphonate compounds
US7045306B2 (en) 2003-04-28 2006-05-16 The General Hospital Corporation Method for identifying compounds in vitro that modulate the dysregulation of transcription of transcription mediated by mutant huntingtin protein
US7214491B2 (en) 2003-05-07 2007-05-08 E. I. Du Pont De Nemours And Company Δ-12 desaturase gene suitable for altering levels of polyunsaturated fatty acids in oleaginous yeasts
WO2004101787A1 (en) 2003-05-14 2004-11-25 Japan Science And Technology Agency Inhibition of the expression of huntington gene
CN1984921B (en) * 2003-06-03 2010-06-16 Isis药物公司 Modulation of survivin expression
EP1635846A4 (en) 2003-06-20 2009-01-28 Coley Pharm Gmbh Small molecule toll-like receptor (tlr) antagonists
WO2005013901A2 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
JP2011088935A (en) 2003-08-08 2011-05-06 Chiralgen Ltd Optically-active nucleoside 3'-phosphoroamidite for production of phosphorus atom modified nucleotide analog
JP2005089441A (en) 2003-08-08 2005-04-07 Toudai Tlo Ltd Manufacturing method of highly stereoregular phosphorus atom-modified nucleotide analogue
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
CA2535800A1 (en) 2003-08-21 2005-03-03 Griffith University Novel sulfenamide oxides
CA2535802A1 (en) 2003-08-21 2005-03-03 Griffith University Novel sulfenamides
JP2007504152A (en) 2003-08-27 2007-03-01 ビオタ， インコーポレイテッド Novel tricyclic nucleosides or nucleotides as therapeutic agents
ES2382807T3 (en) 2003-08-28 2012-06-13 Takeshi Imanishi New artificial nucleic acids of the N-O link type with cross-linking
JP4580870B2 (en) 2003-09-02 2010-11-17 株式会社キラルジェン Method for producing ribonucleotide or ribonucleotide derivative
WO2005028494A1 (en) 2003-09-02 2005-03-31 Takeshi Wada Process for producing 5'-phosphitylated monomer and h-phosphonate oligonucleotide derivative
US20050053981A1 (en) 2003-09-09 2005-03-10 Swayze Eric E. Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
US20050074801A1 (en) 2003-09-09 2005-04-07 Monia Brett P. Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry
MXPA06002660A (en) 2003-09-09 2006-09-04 Geron Corp Modified oligonucleotides for telomerase inhibition.
ES2485848T3 (en) 2003-09-12 2014-08-14 University Of Massachusetts RNA interference for the treatment of disorders related to function gain
US8680063B2 (en) 2003-09-12 2014-03-25 University Of Massachusetts RNA interference for the treatment of gain-of-function disorders
GB0323968D0 (en) 2003-10-13 2003-11-19 Glaxosmithkline Biolog Sa Immunogenic compositions
US8188254B2 (en) 2003-10-30 2012-05-29 Coley Pharmaceutical Gmbh C-class oligonucleotide analogs with enhanced immunostimulatory potency
US20050239102A1 (en) 2003-10-31 2005-10-27 Verdine Gregory L Nucleic acid binding oligonucleotides
US7846436B2 (en) * 2003-11-28 2010-12-07 Chemgenes Corporation Oligonucleotides and related compounds
AU2003300239A1 (en) 2003-12-29 2005-07-21 Galapagos Genomics N.V. Modulators of bone homeostasis identified in a high-throughput screen
JP4945129B2 (en) 2004-01-27 2012-06-06 株式会社キラルジェン Fluorous carrier and method for producing oligonucleotide derivative using the same
US20050176045A1 (en) 2004-02-06 2005-08-11 Dharmacon, Inc. SNP discriminatory siRNA
US20080221303A1 (en) 2004-02-18 2008-09-11 Jehoshua Katzhendler Method for the Preparation of Peptide-Oligonucleotide Conjugates
JP3976742B2 (en) 2004-02-27 2007-09-19 江守商事株式会社 Immunostimulatory oligonucleotides that induce interferon alpha
WO2005085272A1 (en) 2004-03-05 2005-09-15 Takeshi Wada Boranophosphate monomer and process for producing oligonucleotide derivative therefrom
WO2005092909A1 (en) 2004-03-25 2005-10-06 Toudai Tlo, Ltd. Processes for producing ribonucleotide analogue with high stereoregularity and deoxyribonucleotide analogue
US20050244869A1 (en) 2004-04-05 2005-11-03 Brown-Driver Vickie L Modulation of transthyretin expression
EP1737878A2 (en) 2004-04-05 2007-01-03 Alnylam Pharmaceuticals Inc. Process and reagents for oligonucleotide synthesis and purification
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
CA2572795A1 (en) 2004-05-27 2005-12-08 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services Differential expression of molecules associated with acute stroke
US7759318B1 (en) 2004-05-28 2010-07-20 Isis Pharmaceuticals, Inc. Identification of novel pathways, genes and promoter motifs regulating adipogenesis
JP2008501693A (en) 2004-06-03 2008-01-24 アイシス ファーマシューティカルズ、インク． Double-stranded composition with individually regulated strands for use in gene regulation
HUE028632T2 (en) 2004-06-28 2016-12-28 Univ Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
HUE026284T2 (en) 2004-08-10 2016-06-28 Genzyme Corp Oligonucleotides for use in modulating lipoprotein and cholesterol levels in humans
WO2006022323A1 (en) 2004-08-26 2006-03-02 Nippon Shinyaku Co., Ltd. Phosphoramidite compound and method for producing oligo-rna
AU2005282380A1 (en) 2004-09-07 2006-03-16 Archemix Corp. Aptamer medicinal chemistry
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
WO2006031461A2 (en) 2004-09-09 2006-03-23 Isis Pharmaceuticals, Inc. Pyrrolidinyl groups for attaching conjugates to oligomeric compounds
US7919472B2 (en) 2004-09-17 2011-04-05 Isis Pharmaceuticals, Inc. Enhanced antisense oligonucleotides
US20060089325A1 (en) 2004-10-13 2006-04-27 Sanjay Bhanot Antisense modulation of PTP1B expression
US7622451B2 (en) 2004-11-03 2009-11-24 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
EP1807440B1 (en) 2004-11-03 2020-02-19 The University of Kansas Novobiocin analogues as anticancer agents
US8212011B2 (en) 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues
US9120774B2 (en) 2004-11-03 2015-09-01 University Of Kansas Novobiocin analogues having modified sugar moieties
US8212012B2 (en) 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues having modified sugar moieties
KR100721928B1 (en) 2004-11-05 2007-05-28 주식회사 바이오씨에스 Pharmaceutical composition for treating or preventing dermatitis comprising CpG oligodeoxynucleotide
EP1657307A1 (en) 2004-11-16 2006-05-17 Immunotech S.A. Oligonucleotides that induce the secretion of GM-CSF
AU2005313883B2 (en) 2004-12-09 2011-03-31 Alnylam Pharmaceuticals, Inc. Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering RNAs
WO2006065751A2 (en) 2004-12-13 2006-06-22 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
WO2006066260A2 (en) 2004-12-17 2006-06-22 Thiosense, Inc. Compositions of and methods for producing phosphorus-chiral monomers and oligomers
US20070099851A1 (en) 2004-12-30 2007-05-03 Linn Gregory S Stable analogues of ribose-1-phosphate and methods for treating diabetes and other metabolic disorders
US20060183763A1 (en) 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
CN100485034C (en) 2005-01-28 2009-05-06 权滢周 Oligonucleotides extracted from mycobacteria for stimulating immune function, treating immune-related diseases, allergic dermatitis and/or protecting normal immune cells
CA2598992A1 (en) 2005-02-24 2006-08-31 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
WO2006137953A1 (en) 2005-04-01 2006-12-28 The Regents Of The Univerisity Of California Phosphono-pent-2-en-1-yl nucleosides and analogs
BRPI0611452A2 (en) 2005-05-05 2010-09-08 Antisense Pharma Gmbh oligonucleotide dosage
US7902352B2 (en) 2005-05-06 2011-03-08 Medtronic, Inc. Isolated nucleic acid duplex for reducing huntington gene expression
WO2006121960A2 (en) 2005-05-06 2006-11-16 Medtronic, Inc. Methods and sequences to suppress primate huntington gene expression
DK3308788T3 (en) 2005-06-23 2019-01-02 Biogen Ma Inc COMPOSITIONS AND PROCEDURES FOR MODULATING SMN2 SPLASH
US9133517B2 (en) 2005-06-28 2015-09-15 Medtronics, Inc. Methods and sequences to preferentially suppress expression of mutated huntingtin
EP1896586A2 (en) 2005-06-28 2008-03-12 Medtronic, Inc. Methods and sequences to preferentially suppress expression of mutated huntingtin
WO2007005941A2 (en) 2005-07-05 2007-01-11 President And Fellows Of Harvard College Liver targeted conjugates
JP4984634B2 (en) 2005-07-21 2012-07-25 ソニー株式会社 Physical information acquisition method and physical information acquisition device
PT1924252E (en) 2005-07-28 2011-12-16 Id Fish Technology Inc Method for improving cell permeability to foreign particles
JP5523705B2 (en) 2005-08-29 2014-06-18 レグルス・セラピューティクス・インコーポレイテッド Method of using to modulate MIR-122A
WO2007028065A2 (en) 2005-08-30 2007-03-08 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds for modulation of splicing
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
US20070077993A1 (en) 2005-09-30 2007-04-05 Midgley Timothy M Method and apparatus for collecting user game play data and crediting users in a gaming environment
CN104278037B (en) 2005-10-12 2020-09-15 艾德拉药物股份有限公司 Immunomodulatory oligonucleotide (IRO) compounds for modulating Toll-like receptors based on variant response
US9308252B2 (en) 2005-10-27 2016-04-12 Cook Biotech, Inc. Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
CA2627134A1 (en) 2005-10-28 2007-05-03 Tosoh Corporation Method of preparing carotenoid synthesizing microorganism and method of producing carotenoids
AU2006305886C1 (en) 2005-10-28 2011-03-17 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of huntingtin gene
US20090082295A1 (en) 2005-11-11 2009-03-26 Pfizer Inc. Combinations and methods of using an immunomodulatory oligodeoxynucleotide
WO2007064291A1 (en) 2005-11-30 2007-06-07 Jyoti Chattopadhyaya Method and compounds for rna synthesis
ES2707787T3 (en) 2005-12-02 2019-04-05 Ionis Pharmaceuticals Inc Antibacterial analogs of 4,5-substituted aminoglycoside having multiple substituents
US8076303B2 (en) * 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
EP1979356B1 (en) 2005-12-21 2013-09-18 Pfizer Products Inc. Carbonylamino pyrrolopyrazoles, potent kinase inhibitors
JP5425474B2 (en) 2006-01-26 2014-02-26 アイシス ファーマシューティカルズ， インコーポレーテッド Composition and use thereof for huntingtin
CA2640171C (en) 2006-01-27 2014-10-28 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
CA2642152C (en) 2006-02-15 2016-11-01 Coley Pharmaceutical Gmbh Compositions and methods for oligonucleotide formulations
US7759470B2 (en) 2006-02-20 2010-07-20 Roche Diagnostics Operations, Inc. Labeling reagent
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
JP2009533022A (en) 2006-03-31 2009-09-17 アプライド バイオシステムズ， エルエルシー Useful reagents for the synthesis of rhodamine-labeled oligonucleotides
EP2010679A2 (en) 2006-04-06 2009-01-07 Ibis Biosciences, Inc. Compositions for the use in identification of fungi
MX2008013468A (en) 2006-04-20 2008-10-30 Hoffmann La Roche Diazepan derivatives modulators of chemokine receptors.
US8206923B2 (en) 2006-04-24 2012-06-26 Elvira Garza Gonzalez Method for detection and multiple, simultaneous quantification of pathogens by means of real-time polymerase chain reaction
AU2007243412A1 (en) 2006-04-25 2007-11-08 Immune Disease Institute Inc. Targeted delivery to leukocytes using non-protein carriers
GB0608838D0 (en) 2006-05-04 2006-06-14 Novartis Ag Organic compounds
US8158598B2 (en) 2006-05-05 2012-04-17 Isis Pharmaceuticals, Inc. Compositions and their uses directed to PTPR alpha
AU2007258117B2 (en) 2006-05-05 2013-05-30 Isis Pharmaceuticals, Inc. Compounds and methods for modulating gene expression
US20090012120A1 (en) 2006-05-10 2009-01-08 Board Of Trustees Of Michigan State University Synthesis of N-heterocycles, beta-amino acids, and allyl amines via aza-payne mediated reaction of ylides and hydroxy aziridines
ES2389737T3 (en) 2006-05-11 2012-10-31 Isis Pharmaceuticals, Inc. 5 'modified bicyclic nucleic acid analogs
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
DK2034015T3 (en) 2006-05-31 2012-10-15 Toray Industries Immunostimulatory oligonucleotide and its pharmaceutical use
US8097596B2 (en) 2006-06-30 2012-01-17 Lakewood-Amedex, Inc. Compositions and methods for the treatment of muscle wasting
EP2046993A4 (en) 2006-07-07 2010-11-17 Univ Massachusetts Rna silencing compositions and methods for the treatment of huntington's disease
WO2008008476A2 (en) 2006-07-12 2008-01-17 The Regents Of The University Of California Transducible delivery of nucleic acids by reversible phosphotriester charge neutralization protecting groups
US7666888B2 (en) 2006-07-20 2010-02-23 Amgen Inc. Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1
GB0614947D0 (en) 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
US8101585B2 (en) 2006-08-04 2012-01-24 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of JNK proteins
AT504194B1 (en) 2006-09-07 2008-07-15 Oesterr Rotes Kreuz BACTERIA DETECTION
US8138330B2 (en) 2006-09-11 2012-03-20 Sigma-Aldrich Co. Llc Process for the synthesis of oligonucleotides
CN101517082B (en) 2006-09-27 2014-01-22 科勒制药有限责任公司 Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
US9550988B2 (en) 2006-10-18 2017-01-24 Ionis Pharmaceuticals, Inc. Antisense compounds
BRPI0717348A2 (en) 2006-10-23 2013-10-15 Irm Llc COMPOSITIONS AND PROCESSES TO INHIBIT CAPTECINE PROTEASES
AU2007353120A1 (en) 2006-10-26 2008-11-20 Coley Pharmaceutical Gmbh Oligoribonucleotides and uses thereof
FR2908414B1 (en) 2006-11-13 2012-01-20 Centre Nat Rech Scient IMMOBILIZATION OF MEMBRANE PROTEINS ON A SUPPORT THROUGH AN AMPHIPHILE MOLECULE
CA2669917A1 (en) 2006-11-17 2008-05-22 Dawn M. George Aminopyrrolidines as chemokine receptor antagonists
EP2455471A3 (en) 2006-11-27 2012-09-12 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
US7884197B2 (en) 2006-12-12 2011-02-08 Idera Pharmaceuticals, Inc. Synthetic agonists of TLR9
UY30892A1 (en) 2007-02-07 2008-09-02 Smithkline Beckman Corp AKT ACTIVITY INHIBITORS
EP2125852B1 (en) 2007-02-15 2016-04-06 Ionis Pharmaceuticals, Inc. 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom
KR20150090284A (en) 2007-03-24 2015-08-05 젠자임 코포레이션 Administering antisense oligonucleotides complementary to human apolipoprotein b
US7960353B2 (en) 2007-05-10 2011-06-14 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
EP2158316B1 (en) 2007-05-11 2015-04-15 Adynxx, Inc. Gene expression and pain
EP2149571A4 (en) 2007-05-24 2010-09-01 Kyorin Seiyaku Kk Mutilin derivative having heterocyclic aromatic ring carboxylic acid structure in substituent at 14-position
GB0710186D0 (en) 2007-05-29 2007-07-04 Texas Instr Denmark PWM loop with minimum allasing error property
WO2008150729A2 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
AU2008258599B2 (en) 2007-06-05 2013-06-13 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
EP2173760B2 (en) 2007-06-08 2015-11-04 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
WO2008151833A2 (en) 2007-06-13 2008-12-18 Hochschule Mannheim Compounds for the modulation of huntingtin aggregation, methods and means for identifying such compounds
EP2014769B1 (en) 2007-06-18 2010-03-31 Commissariat à l'Energie Atomique Reversible siRNAa-based silencing of mutated and endogenous wild-type huntingtin gene and its application for the treatment of Huntington's disease
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
US8278283B2 (en) 2007-07-05 2012-10-02 Isis Pharmaceuticals, Inc. 6-disubstituted or unsaturated bicyclic nucleic acid analogs
WO2009014887A2 (en) 2007-07-09 2009-01-29 Idera Pharmaceuticals, Inc. Stabilized immune modulatory rna (simra) compounds
TWI413530B (en) 2007-07-20 2013-11-01 Kao Corp Organopolysiloxane
CA2694718A1 (en) 2007-07-31 2009-02-05 University Of Saskatchewan Genetic variation in pro-melanin-concentrating hormone gene affects carcass traits in cattle
US7812003B2 (en) 2007-08-02 2010-10-12 Safe Stephen H Antisense microRNA and uses therefor
AU2008286735A1 (en) 2007-08-15 2009-02-19 Idera Pharmaceuticals, Inc. Toll like receptor modulators
BRPI0817527A2 (en) 2007-10-01 2017-05-02 Isis Pharmaceuticals Inc antisense modulation of human fibroblast growth factor receptor expression 4
KR100886139B1 (en) 2007-11-13 2009-02-27 주식회사 삼천리제약 Method for preparing oligonucleotide
PE20091669A1 (en) 2007-12-21 2009-12-06 Exelixis Inc BENZOFUROPYRIMIDINONES
TWI340765B (en) 2007-12-26 2011-04-21 Ind Tech Res Inst Oligonucleotide sequences and dna chip for identifying filamentous microorganisms and the identification method thereof
WO2009089659A1 (en) 2008-01-18 2009-07-23 Shanghai Targetdrug Co., Ltd. Pyrollidine-based compounds
JP2011515653A (en) 2008-02-04 2011-05-19 ガラパゴス・ナムローゼ・フェンノートシャップ Target sequences useful for the treatment of neurodegenerative diseases and methods for identifying them
JP2009190983A (en) 2008-02-12 2009-08-27 Tokyo Institute Of Technology Oligonucleotide derivative
WO2009117589A1 (en) 2008-03-21 2009-09-24 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising tricyclic nucleosides and methods for their use
WO2009142822A2 (en) 2008-03-26 2009-11-26 Alnylam Pharmaceuticals, Inc. 2-f modified rna interference agents
WO2009146123A2 (en) 2008-04-03 2009-12-03 Spring Bank Compositions and methods for treating viral infections
WO2009121347A1 (en) 2008-04-04 2009-10-08 Universität Hamburg Method for the stereoselective synthesis of phosphorus compounds
US9290534B2 (en) 2008-04-04 2016-03-22 Ionis Pharmaceuticals, Inc. Oligomeric compounds having at least one neutrally linked terminal bicyclic nucleoside
CA2726866A1 (en) 2008-05-09 2009-11-12 The University Of British Columbia Methods and compositions for the treatment of huntington's disease
US8679750B2 (en) 2008-05-09 2014-03-25 The University Of British Columbia Methods and compositions for the treatment of Huntington'S disease
AU2009246169B2 (en) 2008-05-15 2015-01-22 Dynavax Technologies Corporation Long term disease modification using immunostimulatory oligonucleotides
WO2009143390A2 (en) 2008-05-22 2009-11-26 Isis Pharmaceuticals, Inc. Methods for modulating expression of rbp4
WO2009143391A2 (en) 2008-05-22 2009-11-26 Isis Pharmaceuticals, Inc Methods for modulation expression of creb
US8541387B2 (en) 2008-05-22 2013-09-24 Isis Pharmaceuticals, Inc. Modulation of SMRT expression
WO2009148605A2 (en) 2008-06-04 2009-12-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
WO2010003133A2 (en) 2008-07-03 2010-01-07 Exelixis Inc. Cdk modulators
US8410070B2 (en) 2008-09-12 2013-04-02 University Of Louisville Research Foundation, Inc. Compositions and methods for treating cancer, inhibiting proliferation, and inducing cell death
US8163707B2 (en) 2008-09-15 2012-04-24 Enanta Pharmaceuticals, Inc. 4′-allene-substituted nucleoside derivatives
EP2346883B1 (en) 2008-09-23 2016-03-23 Scott G. Petersen Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
EP2356129B1 (en) 2008-09-24 2013-04-03 Isis Pharmaceuticals, Inc. Substituted alpha-l-bicyclic nucleosides
US8604192B2 (en) 2008-09-24 2013-12-10 Isis Pharmaceuticals, Inc. Cyclohexenyl nucleic acids analogs
CN102238967A (en) 2008-10-07 2011-11-09 哈佛大学校长及研究员协会 Telomerase inhibitors and methods of use thereof
DK2350279T3 (en) 2008-10-22 2016-02-15 Quark Pharmaceuticals Inc METHODS OF TREATING EYE DISEASES
US8987435B2 (en) 2008-10-24 2015-03-24 Isis Pharmaceuticals, Inc. Oligomeric compounds and methods
US8883752B2 (en) 2008-10-24 2014-11-11 Isis Pharmaceuticals, Inc. 5′ and 2′ BIS-substituted nucleosides and oligomeric compounds prepared therefrom
ES2616051T3 (en) 2008-12-02 2017-06-09 Wave Life Sciences Japan, Inc. Method for the synthesis of modified nucleic acids in the phosphorus atom
CN102307889A (en) 2008-12-23 2012-01-04 集润德斯股份公司 Sulfurizing reagents and their use for oligonucleotides synthesis
WO2010080953A1 (en) 2009-01-08 2010-07-15 Isis Pharmaceuticals, Inc. Transgenic murine model of human lipoprotein metabolism, hypercholesterolemia and cardiovascular disease
KR20100087540A (en) 2009-01-28 2010-08-05 삼성전자주식회사 Ink composition for inkjet recording
WO2010091301A1 (en) 2009-02-06 2010-08-12 Isis Pharmaceuticals, Inc. Oligomeric compounds and excipients
US8202974B2 (en) 2009-02-10 2012-06-19 Idera Pharmaceuticals, Inc. Synthetic RNA-based agonists of TLR7
JP5766617B2 (en) 2009-02-20 2015-08-19 ユニバーシティ・オブ・カンザス Novobiocin analogs having modified sugar moieties
WO2010101951A1 (en) 2009-03-02 2010-09-10 Alnylam Pharmaceuticals, Inc. Nucleic acid chemical modifications
EP2408796B1 (en) 2009-03-16 2020-04-22 Ionis Pharmaceuticals, Inc. Targeting Apolipoprotein B for the reduction of Apolipoprotein C-III
US8653254B2 (en) 2009-03-31 2014-02-18 Takeda Pharmaceutical Company Limited Process for producing nucleoside
US8987222B2 (en) 2009-04-08 2015-03-24 University Of Massachusetts Single nucleotide polymorphism (SNP) targeting therapies for the treatment of huntington'S disease
CA2759098A1 (en) 2009-04-14 2010-10-21 Smith Holdings, Llc Methods and compositions for the treatment of medical conditions involving cellular programming
US9260493B2 (en) 2009-05-07 2016-02-16 The Regents Of The University Of California Transducible delivery of nucleic acids using modified dsRNA binding domains
EP2438079A4 (en) 2009-06-01 2013-05-22 Univ California Nucleic acid delivery compositions and methods of use thereof
MX2011012836A (en) 2009-06-05 2012-04-20 Infectious Disease Res Inst Synthetic glucopyranosyl lipid adjuvants.
EP3643783A1 (en) 2009-06-17 2020-04-29 Biogen MA Inc. Compositions and methods for modulation of smn2 splicing in a subject
JP5670097B2 (en) 2009-06-19 2015-02-18 花王株式会社 Two-layer separated hair cosmetic
US20120108800A1 (en) 2009-06-23 2012-05-03 Shumpei Murata Method for synthesizing nucleic acid
AU2010270714B2 (en) 2009-07-06 2015-08-13 Wave Life Sciences Ltd. Novel nucleic acid prodrugs and methods use thereof
US8329024B2 (en) 2009-07-06 2012-12-11 Ada Technologies, Inc. Electrochemical device and method for long-term measurement of hypohalites
WO2011005860A2 (en) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. 5' phosphate mimics
EP2451974A2 (en) 2009-07-08 2012-05-16 Idera Pharmaceuticals, Inc. Oligonucleotide-based compounds as inhibitors of toll-like receptors
WO2011010706A1 (en) 2009-07-23 2011-01-27 武田薬品工業株式会社 Fgf21 cis-element binding substance
WO2011015573A1 (en) 2009-08-03 2011-02-10 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
WO2011015572A1 (en) 2009-08-03 2011-02-10 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
UA107360C2 (en) 2009-08-05 2014-12-25 Biogen Idec Inc Bicyclic aryl sphingosine 1-phosphate analogs
EP2462153B1 (en) 2009-08-06 2015-07-29 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
US8927553B2 (en) 2009-08-10 2015-01-06 Daljit Singh Dhanoa Deuterium-enriched alkyl sulfonamides and uses thereof
NZ714887A (en) 2009-09-11 2019-07-26 Ionis Pharmaceuticals Inc Modulation of huntingtin expression
WO2011034072A1 (en) 2009-09-16 2011-03-24 株式会社キラルジェン Novel protecting group for synthesizing rna and derivative thereof
WO2011038288A1 (en) 2009-09-25 2011-03-31 Isis Pharmaceuticals, Inc. Modulation of ttc39 expression to increase hdl
CA2776028C (en) 2009-10-15 2015-12-01 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds
TWI475051B (en) 2009-11-18 2015-03-01 Kao Corp Organic polysiloxane
JP5809408B2 (en) 2009-11-25 2015-11-10 花王株式会社 Hair cosmetics
US8735417B2 (en) 2009-12-17 2014-05-27 Merck Sharp & Dohme Corp. Aminopyrimidines as Syk inhibitors
US8647742B2 (en) 2009-12-28 2014-02-11 Achira Labs Pvt. Ltd. Diagnostic gel composition, method for making a diagnostic gel composition
WO2011085271A2 (en) 2010-01-08 2011-07-14 Isis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
US8750507B2 (en) 2010-01-25 2014-06-10 Cisco Technology, Inc. Dynamic group creation for managed key servers
EP3321361B1 (en) 2010-02-08 2019-03-27 Ionis Pharmaceuticals, Inc. Selective reduction of allelic variants
US9006198B2 (en) 2010-02-08 2015-04-14 Isis Pharmaceuticals, Inc. Selective reduction of allelic variants
RS53745B1 (en) 2010-02-10 2015-06-30 Glaxosmithkline Llc 6-amino-2-{[(1s)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8h-purin-8-one maleate
US8859755B2 (en) 2010-03-05 2014-10-14 Chiralgen, Ltd. Method for preparing ribonucleoside phosphorothioate
WO2011127175A1 (en) 2010-04-06 2011-10-13 Isis Pharmaceuticals, Inc. Modulation of cd130 (gp130) expression
AU2011237426A1 (en) 2010-04-07 2012-11-22 Isis Pharmaceuticals, Inc. Modulation of CETP expression
WO2011133871A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. 5'-end derivatives
EP2625186B1 (en) 2010-04-28 2016-07-27 Ionis Pharmaceuticals, Inc. 5' modified nucleosides and oligomeric compounds prepared therefrom
WO2011139702A2 (en) 2010-04-28 2011-11-10 Isis Pharmaceuticals, Inc. Modified nucleosides and oligomeric compounds prepared therefrom
US20130156845A1 (en) 2010-04-29 2013-06-20 Alnylam Pharmaceuticals, Inc. Lipid formulated single stranded rna
WO2011135396A1 (en) 2010-04-30 2011-11-03 Cellectis Method for modulating double-strand break-induced homologous recombination
GB201008902D0 (en) 2010-05-27 2010-07-14 Imp Innovations Ltd Membrane enhanced polymer sythesis
JP2013541510A (en) 2010-08-31 2013-11-14 メルク・シャープ・エンド・ドーム・コーポレイション Novel single chemical and oligonucleotide delivery method
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
CN103080314B (en) 2010-09-30 2016-04-13 Lsip基金运营联合公司 Dominant mutant genes expression inhibitor
KR101381048B1 (en) 2010-10-20 2014-04-14 씨제이제일제당 (주) A microorganism producing O-phosphoserine and the method of producing L-cysteine or derivatives thereof from O-phosphoserine using the same
EP3327125B1 (en) 2010-10-29 2020-08-05 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
AU2011325956B2 (en) 2010-11-12 2016-07-14 The General Hospital Corporation Polycomb-associated non-coding RNAs
EP2647644B1 (en) 2010-11-30 2020-09-09 Wave Life Sciences Japan, Inc. 2'-o-modified rna
US20140050778A1 (en) 2010-12-28 2014-02-20 University Of Rochester Nucleic acid binding compounds, methods of making, and use thereof
EP3467109A1 (en) 2011-02-08 2019-04-10 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
WO2012109667A1 (en) 2011-02-12 2012-08-16 University Of Iowa Research Foundation Therapeutic compounds
US9353371B2 (en) 2011-05-02 2016-05-31 Ionis Pharmaceuticals, Inc. Antisense compounds targeting genes associated with usher syndrome
FR2975600B1 (en) 2011-05-24 2013-07-05 Assist Publ Hopitaux De Paris AGENTS FOR THE TREATMENT OF TUMORS
EP2734208B1 (en) 2011-07-19 2017-03-01 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
EP2734525A4 (en) 2011-07-19 2015-03-04 Univ Idaho Embodiments of a probe and method for targeting nucleic acids
DK2742136T3 (en) 2011-08-11 2017-11-20 Ionis Pharmaceuticals Inc GAPMER COMPOUNDS INCLUDING 5 'MODIFIED DEOXYRIBONUCLEOSIDES IN GAP AND APPLICATIONS THEREOF
EP2751269B1 (en) 2011-08-29 2016-03-23 Ionis Pharmaceuticals, Inc. Methods and compounds useful in conditions related to repeat expansion
US20140080896A1 (en) 2011-08-30 2014-03-20 The Regents Of The University Of California Identification of small molecules that facilitate therapeutic exon skipping
DK2751284T3 (en) 2011-08-31 2017-03-27 Univ Manchester PROCEDURE FOR DIAGNOSTICING A NEURODEGENERATIVE DISEASE
WO2013036833A1 (en) 2011-09-09 2013-03-14 Mayo Foundation For Medical Education And Research Detecting frontotemporal dementia and amyotrophic lateral sclerosis
US10066228B2 (en) 2011-11-30 2018-09-04 Sarepta Therapeutics, Inc. Oligonucleotides for treating expanded repeat diseases
KR200460641Y1 (en) 2011-12-07 2012-06-04 이형호 Easy to carry wine glass
JP2015502365A (en) 2011-12-12 2015-01-22 オンコイミューニン，インコーポレイティド In vivo delivery of oligonucleotides
JP6112569B2 (en) 2011-12-16 2017-04-12 国立大学法人 東京医科歯科大学 Chimeric duplex nucleic acid
CN102675386B (en) 2011-12-24 2014-07-02 河南科技大学 Method for separating and purifying gentiamarin
WO2013134558A1 (en) 2012-03-07 2013-09-12 The Texas A & M University System Cancer treatment targeting non-coding rna overexpression
PT2834258T (en) 2012-03-13 2017-04-07 Gilead Sciences Inc 2'- substituted carba-nucleoside analogs for antiviral treatment
KR20130114435A (en) 2012-04-09 2013-10-17 삼성전자주식회사 Biomolecule detection apparatus including a plurality of electrode
EP3228712A1 (en) 2012-04-23 2017-10-11 BioMarin Technologies B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders
AU2013266393B2 (en) 2012-05-22 2017-09-28 Idenix Pharmaceuticals Llc D-amino acid compounds for liver disease
WO2013179412A1 (en) 2012-05-30 2013-12-05 北海道システム・サイエンス株式会社 Oligonucleotide synthesis method using highly dispersible liquid-phase support
JP6246121B2 (en) 2012-07-13 2017-12-13 株式会社新日本科学 Chiral nucleic acid adjuvant
CN107011400B (en) 2012-07-13 2021-05-25 波涛生命科学有限公司 Asymmetric auxiliary group
MX2015000577A (en) 2012-07-13 2015-08-14 Wave Life Sciences Pte Ltd Chiral control.
WO2014025805A1 (en) 2012-08-06 2014-02-13 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugated rna agents and process for their preparation
EP2885312A4 (en) 2012-08-15 2016-01-20 Isis Pharmaceuticals Inc Method of preparing oligomeric compounds using modified capping protocols
EP3459549B1 (en) 2012-10-12 2022-04-06 Ionis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
PT2906696T (en) 2012-10-15 2019-12-16 Univ California Methods for modulating c9orf72 expression
US10443052B2 (en) 2012-10-15 2019-10-15 Ionis Pharmaceuticals, Inc. Compositions for modulating C9ORF72 expression
US10577604B2 (en) 2012-10-15 2020-03-03 Ionis Pharmaceuticals, Inc. Methods for monitoring C9ORF72 expression
CN104884462A (en) 2012-10-29 2015-09-02 共晶制药股份有限公司 Pyrimidine nucleotides and their monophosphate prodrugs for treatment of viral infections and cancer
EP2725029A1 (en) 2012-10-29 2014-04-30 Laboratoire Biodim New antibacterial compounds and biological applications thereof
WO2014069520A1 (en) 2012-10-31 2014-05-08 武田薬品工業株式会社 New modified nucleic acid
EP2920304B1 (en) 2012-11-15 2019-03-06 Roche Innovation Center Copenhagen A/S Oligonucleotide conjugates
WO2014080004A1 (en) 2012-11-26 2014-05-30 Santaris Pharma A/S Compositions and methods for modulation of fgfr3 expression
US9211300B2 (en) 2012-12-19 2015-12-15 Idenix Pharmaceuticals Llc 4′-fluoro nucleosides for the treatment of HCV
WO2014118272A1 (en) 2013-01-30 2014-08-07 Santaris Pharma A/S Antimir-122 oligonucleotide carbohydrate conjugates
DK2951305T3 (en) 2013-01-30 2018-10-29 Hoffmann La Roche LNA oligonucleotide KULHYDRATKONJUGATER
EP3778618A1 (en) 2013-02-04 2021-02-17 Ionis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
AU2014219019B2 (en) 2013-02-22 2020-04-16 Sirna Therapeutics, Inc. Short interfering nucleic acid (siNA) molecules containing a 2' internucleoside linkage
AU2014222150A1 (en) 2013-03-01 2015-09-10 National University Corporation Tokyo Medical And Dental University Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent
JP2016515552A (en) 2013-03-28 2016-05-30 シンジェンタ パーティシペーションズ アーゲー Neonicotinoid-resistant pest control method
CA2907511A1 (en) 2013-03-28 2014-10-02 Syngenta Participations Ag Methods of controlling neonicotinoid resistant pests
NZ631512A (en) 2013-05-01 2016-10-28 Ionis Pharmaceuticals Inc Compositions and methods for modulating apolipoprotein (a) expression
CN105247052A (en) 2013-05-24 2016-01-13 罗氏创新中心哥本哈根有限公司 Oligonucleotide modulators of B-cell CLL/lymphoma LLA (BCL11A) and uses thereof
CN105228999B (en) 2013-05-24 2021-03-02 味之素株式会社 Process for preparing morpholino oligonucleotides
WO2014192310A1 (en) 2013-05-30 2014-12-04 National University Corporation Tokyo Medical And Dental University Double-stranded agents for delivering therapeutic oligonucleotides
CN105324119A (en) 2013-06-16 2016-02-10 国立大学法人东京医科齿科大学 Double-stranded antisense nucleic acid with exon-skipping effect
US20160122761A1 (en) 2013-06-21 2016-05-05 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of target nucleic acids
MY183049A (en) 2013-06-27 2021-02-09 Roche Innovation Ct Copenhagen As Antisense oligomers and conjugates targeting pcsk9
TWI657819B (en) 2013-07-19 2019-05-01 美商Ionis製藥公司 Compositions for modulating tau expression
CA2919268C (en) 2013-07-25 2023-09-05 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
US10435430B2 (en) 2013-07-31 2019-10-08 Ionis Pharmaceuticals, Inc. Methods and compounds useful in conditions related to repeat expansion
US20160214974A1 (en) 2013-09-06 2016-07-28 Syngenta Participations Ag Insecticidal compounds
EP3052511A4 (en) 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
AU2014329452B2 (en) 2013-10-03 2019-06-20 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015051366A2 (en) 2013-10-04 2015-04-09 Novartis Ag Novel formats for organic compounds for use in rna interference
CN112080502A (en) 2013-10-11 2020-12-15 Ionis制药公司 Compositions for modulating expression of C9ORF72
EP3058068B1 (en) 2013-10-14 2019-04-24 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of c9orf72 antisense transcript
ES2747260T3 (en) 2013-10-14 2020-03-10 Ionis Pharmaceuticals Inc Methods for modulating expression of C9ORF72 antisense transcript
AU2014346424B2 (en) 2013-11-11 2020-09-17 Sangamo Therapeutics, Inc. Methods and compositions for treating Huntington's Disease
US20160289677A1 (en) 2013-11-14 2016-10-06 Roche Innovation Center Copenhagen A/S APOB Antisense Conjugate Compounds
EP2918275B1 (en) 2013-12-13 2016-05-18 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
US10149905B2 (en) 2014-01-15 2018-12-11 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
KR102423317B1 (en) 2014-01-16 2022-07-22 웨이브 라이프 사이언시스 리미티드 Chiral design
WO2015143078A1 (en) 2014-03-18 2015-09-24 University Of Massachusetts Raav-based compositions and methods for treating amyotrophic lateral sclerosis
EP3137476B1 (en) 2014-04-28 2019-10-09 Ionis Pharmaceuticals, Inc. Linkage modified oligomeric compounds
PT3137605T (en) 2014-05-01 2020-12-18 Ionis Pharmaceuticals Inc Compositions and methods for modulating angiopoietin-like 3 expression
BR112016025849A2 (en) 2014-05-08 2017-10-17 Chdi Foundation Inc methods and compositions for the treatment of huntington's disease
AU2015264263B2 (en) 2014-05-20 2021-08-05 University Of Iowa Research Foundation Huntington's disease therapeutic compounds
US20160017327A1 (en) 2014-07-11 2016-01-21 The Johns Hopkins University Phosphorodiamidate morpholino oligomers (pmos) and their use in suppression of mutant huntingtin expression and attenuation of neurotoxicity
CA2955250A1 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Chimeric polynucleotides
EP2982758A1 (en) 2014-08-04 2016-02-10 Centre Hospitalier Universitaire Vaudois (CHUV) Genome editing for the treatment of huntington's disease
EP3178807B1 (en) 2014-08-07 2020-04-29 Takeda Pharmaceutical Company Limited Cationic lipid
WO2016024205A1 (en) 2014-08-15 2016-02-18 Pfizer Inc. Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene
WO2016027168A2 (en) 2014-08-20 2016-02-25 Lifesplice Pharma Llc Splice modulating oligonucleotides and methods of use thereof
WO2016037191A1 (en) 2014-09-05 2016-03-10 Health Research, Inc. Use of huntingtin-derived plasmids and peptides for active immunization as a huntington's disease (hd) therapeutic
WO2016081444A1 (en) 2014-11-17 2016-05-26 Alnylam Pharmaceuticals, Inc. Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
WO2016079181A1 (en) 2014-11-19 2016-05-26 Roche Innovation Center Copenhagen A/S Lna gapmer oligonucleotides comprising chiral phosphorothioate linkages
JP6689279B2 (en) 2014-12-16 2020-05-20 ロシュ イノベーション センター コペンハーゲン エーエス Chiral toxicity screening method
CA2971920A1 (en) 2014-12-24 2016-06-30 Uniqure Ip B.V. Rnai induced huntingtin gene suppression
US9688707B2 (en) 2014-12-30 2017-06-27 Ionis Pharmaceuticals, Inc. Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
US10793855B2 (en) 2015-01-06 2020-10-06 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of C9ORF72 antisense transcript
US20180023081A1 (en) 2015-02-04 2018-01-25 Bristol-Myers Squibb Company Lna oligonucleotides with alternating flanks
SG11201706293XA (en) 2015-02-04 2017-09-28 Hoffmann La Roche Tau antisense oligomers and uses thereof
JP6772156B2 (en) 2015-02-04 2020-10-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ How to choose a therapeutic molecule
MY194175A (en) 2015-02-10 2022-11-17 Genzyme Corp Variant rnai
CA2976445A1 (en) 2015-02-13 2016-08-18 Alnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
EP3262174A4 (en) 2015-02-23 2018-10-17 Ionis Pharmaceuticals, Inc. Compounds and methods for increasing antisense activity
WO2016141236A1 (en) 2015-03-03 2016-09-09 Ionis Pharmaceuticals, Inc. Compositions for modulating mecp2 expression
WO2016145142A1 (en) 2015-03-10 2016-09-15 Emory University Nucleotide and nucleoside therapeutics compositions and uses related thereto
WO2016154096A1 (en) 2015-03-20 2016-09-29 Ionis Pharmaceuticals, Inc. Modulation of smggds expression
CN107980062B (en) 2015-04-03 2022-11-25 马萨诸塞大学 Oligonucleotide compounds for targeting huntingtin mRNA
US10851371B2 (en) 2015-04-10 2020-12-01 Ionis Pharmaceuticals, Inc. Modulation of SMN expression
WO2016167780A1 (en) 2015-04-16 2016-10-20 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of c9orf72 antisense transcript
KR102104163B1 (en) 2015-04-16 2020-04-23 아이오니스 파마수티컬즈, 인코포레이티드 Composition for modulating C9ORF72 expression
WO2016209862A1 (en) 2015-06-23 2016-12-29 Alnylam Pharmaceuticals, Inc. Glucokinase (gck) irna compositions and methods of use thereof
CA2990699A1 (en) 2015-06-29 2017-01-05 Ionis Pharmaceuticals, Inc. Modified crispr rna and modified single crispr rna and uses thereof
ES2917181T3 (en) 2015-07-10 2022-07-07 Ionis Pharmaceuticals Inc Diacylglycerol acyltransferase 2 (DGAT2) modulators
US10494632B2 (en) 2015-07-10 2019-12-03 Alnylam Pharmaceuticals, Inc. Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
JP2018520683A (en) 2015-07-17 2018-08-02 アルニラム ファーマスーティカルズ インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Multi-target single-body conjugates
MA43072A (en) 2015-07-22 2018-05-30 Wave Life Sciences Ltd COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
TW201718620A (en) 2015-07-27 2017-06-01 阿尼拉製藥公司 Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereof
DK3329002T3 (en) 2015-07-31 2021-01-11 Alnylam Pharmaceuticals Inc TRANSTHYRETIN (TTR) IRNA COMPOSITIONS AND METHODS FOR USING IT FOR THE TREATMENT OR PREVENTION OF TTR-ASSOCIATED DISEASES
WO2017032726A1 (en) 2015-08-24 2017-03-02 Roche Innovation Center Copenhagen A/S Lna-g process
IL310959A (en) 2015-08-25 2024-04-01 Alnylam Pharmaceuticals Inc Methods and compositions for treating a proprotein convertase subtilisin kexin (pcsk9) gene-associated disorder
EP3344769B1 (en) 2015-09-02 2024-04-17 Alnylam Pharmaceuticals, Inc. Programmed cell death 1 ligand 1 (pd-l1) irna compositions and methods of use thereof
WO2017048620A1 (en) 2015-09-14 2017-03-23 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof
WO2017059446A1 (en) 2015-10-01 2017-04-06 Memorial Sloan-Kettering Cancer Center Anthranilyl-adenosinemonosulfamate analogs and uses thereof
EP3356447A4 (en) 2015-10-01 2019-06-12 Memorial Sloan-Kettering Cancer Center Inhibitors of menaquinone biosynthesis
EP3355932B1 (en) 2015-10-02 2023-04-12 Roche Innovation Center Copenhagen A/S Oligonucleotide conjugation process
BR112018006636B1 (en) 2015-10-09 2023-03-28 Wave Life Sciences Ltd OLIGONUCLEOTIDE COMPOSITION, PHARMACEUTICAL COMPOSITION AND USE OF THE OLIGONUCLEOTIDE COMPOSITION
US10955407B2 (en) 2015-10-22 2021-03-23 Roche Innovation Center Copenhagen A/S In vitro toxicity screening assay
WO2017068087A1 (en) 2015-10-22 2017-04-27 Roche Innovation Center Copenhagen A/S Oligonucleotide detection method
US11260073B2 (en) 2015-11-02 2022-03-01 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating C90RF72
CN116064539A (en) 2015-11-12 2023-05-05 豪夫迈·罗氏有限公司 Oligonucleotides for inducing expression of parent UBE3A
JP7286320B2 (en) 2016-03-13 2023-06-05 ウェイブ ライフ サイエンシズ リミテッド Compositions and methods for phosphoramidite and oligonucleotide synthesis
ES2857702T3 (en) 2016-03-14 2021-09-29 Hoffmann La Roche Oligonucleotides for reduction of PD-L1 expression
EP3430021A1 (en) 2016-03-18 2019-01-23 Roche Innovation Center Copenhagen A/S Acyl-protected l-lna-guanosine monomers
WO2017165489A1 (en) 2016-03-23 2017-09-28 Emory University Antiviral agents for treating zika and dengue virus infections
AU2017248637A1 (en) 2016-04-13 2018-09-27 Ionis Pharmaceuticals, Inc. Methods for reducing C9ORF72 expression
JP6985288B2 (en) 2016-04-14 2021-12-22 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Trityl-mono-GalNAc compounds and their uses
MA45270A (en) 2016-05-04 2017-11-09 Wave Life Sciences Ltd COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
MA45290A (en) 2016-05-04 2019-03-13 Wave Life Sciences Ltd PROCESSES AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS
CN109311925B (en) 2016-05-12 2022-06-03 罗氏创新中心哥本哈根有限公司 Enhanced coupling of sterically defined oxaazaphospholane phosphoramidite monomers to nucleosides or oligonucleotides
EP3455354B1 (en) 2016-05-13 2023-07-12 Roche Diagnostics GmbH Protein-based sample collection matrices and devices
US10882884B2 (en) 2016-05-18 2021-01-05 Eth Zurich Stereoselective synthesis of phosphorothioate oligoribonucleotides
US11013757B2 (en) 2016-06-03 2021-05-25 Wave Life Sciences Ltd. Oligonucleotides, compositions and methods thereof
EP3473270B1 (en) 2016-06-20 2022-11-30 Genahead Bio, Inc. Antibody-drug conjugate
US20190264267A1 (en) 2016-07-25 2019-08-29 Wave Life Sciences Ltd. Phasing
CN110088113A (en) 2016-11-23 2019-08-02 波涛生命科学有限公司 Composition and method for phosphoramidite and oligonucleotide synthesis

Also Published As

Publication number Publication date
KR20120046238A (en) 2012-05-09
CL2012000021A1 (en) 2012-07-20
WO2011005761A1 (en) 2011-01-13
US20120316224A1 (en) 2012-12-13
IL217370A (en) 2017-09-28
AU2010270714B2 (en) 2015-08-13
BR112012000828A2 (en) 2016-02-23
MX2012000380A (en) 2012-05-23
IN2012DN00720A (en) 2015-06-19
IL217370A0 (en) 2012-02-29
MX342945B (en) 2016-10-18
EP2451461A1 (en) 2012-05-16
CA2767253A1 (en) 2011-01-13
EP2451461A4 (en) 2013-05-29
RU2612521C2 (en) 2017-03-09
CN102596204A (en) 2012-07-18
JP2012532199A (en) 2012-12-13
JP2015205910A (en) 2015-11-19
US10307434B2 (en) 2019-06-04
KR101885383B1 (en) 2018-08-03
SG177564A1 (en) 2012-02-28
CN102596204B (en) 2016-11-23
RU2012102480A (en) 2013-08-20
AU2010270714A1 (en) 2012-02-16
JP5998326B2 (en) 2016-09-28
US9744183B2 (en) 2017-08-29
BR112012000828A8 (en) 2017-10-10
US20160347784A1 (en) 2016-12-01
SG10201403841QA (en) 2014-09-26

Similar Documents

Publication Publication Date Title
WO2011005761A8 (en) Novel nucleic acid prodrugs and methods of use thereof
SG10201503327QA (en) Production of nucleic acid
GB0910302D0 (en) Nucleic acid amplification
HK1159250A1 (en) Improved method of rna display rna
EP2113570A4 (en) Method of producing l-amino acid
HK1137486A1 (en) Microbiological production of 3-hydroxyisobutyric acid
EP2248906A4 (en) Method of producing l-amino acid
GB201209132D0 (en) Compositions and methods for targeted nucleic acid sequence selection and amplification
WO2010135536A9 (en) Methods of modulating uric acid levels
GB0814570D0 (en) Isolation of nucleic acid
EP2129388A4 (en) Rna targeting compounds and methods for making and using same
EP2130924A4 (en) Method for production of l-amino acid or nucleic acid
IL208374A0 (en) Double-stranded lipid-modified rna having high rna interference effect
IL216109A0 (en) Production of ammonium phosphates
EP2318508A4 (en) Determination of the integrity of rna
GB0812862D0 (en) Nucleic acid amplification
EP2328907A4 (en) Hydrolases, nucleic acids encoding them and methods for making and using them
EP2438184A4 (en) A method of nucleic acid amplification
EP2195453A4 (en) Method of amplifying nucleic acid
ZA201202210B (en) Improved nucleic acid quantitation method
IL217247A0 (en) Dermaseptin b2 as an inhibitor of tumor growth
GB0903562D0 (en) RNA molecules
EP2455470A4 (en) Method for amplifying nucleic acid
AU2009903350A0 (en) Method of cloning DNA
AU2009904217A0 (en) Improved phosphorous removal method

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080039607.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10797719

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 217370

Country of ref document: IL

Ref document number: 2767253

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2012519668

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2012/000380

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2010797719

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010270714

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 720/DELNP/2012

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20127003240

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012102480

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2010270714

Country of ref document: AU

Date of ref document: 20100706

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13381323

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012000828

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012000828

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120106